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1- Introduction:  
 
1.1. Background: 
Since the first human percutaneous transluminal angioplasty (PTCA) was performed  
in 1977, the use of this procedure has increased dramatically, becoming one of the  
most common medical interventions performed. The technique, initially developed in  
Switzerland by Andreas Grüntzig, has transformed the practice of revascularization  
for coronary artery disease (CAD) [20]. The growth of percutaneous coronary  
interventions (PCI) has been remarkable, more than one million PCIs are performed  
worldwide each year. Subsequently, the concept of endovascular prostheses  
(Stents) was developed. In 1987 Sigwart et al. reported the successful implantation  
of stents into coronary arteries of 8 patients [53]. In 1994 two large trials  
demonstrated the superiority of stenting over conventional angioplasty with  
reductions of restenosis rates by 30% compared to balloon angioplasty [15, 50].     
Advances in catheter technology, operators experience, and adjunctive drug therapy  
have improved early outcomes after PTCA, procedural success > 90% and  
complication rates < 5% are readily achieved. Despite these advances, long-term  
outcome is still limited by restenosis. Depending on the definition used, angiographic  
restenosis has been reported in as many as 50% of patients within 6 months after  
balloon angioplasty which required repeated revascularization in approximately 20- 
30% of patients. Although stent implantation has been shown to reduce restenosis as  
compared with PTCA, in-stent restenosis (ISR) still occurs in 10-30% of the patients 
[64]. 
Following successful PTCA and stent implantation, intimal repair processes are  
initiated leading to restenosis in the treated vessel segment.  
 
Experimental evidence suggests five major mechanisms causing restenosis after  
 
PTCA and stent implantation: 1- elastic recoil, 2- thrombus formation,  
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3- inflammation, 4- proliferation of vascular smooth muscle cells (VSMCs), and  
 
5- excessive production of extra-cellular matrix. As elastic recoil is counteracted  
 
by stent, this mechanism is currently of minor importance [22, 26, 64]. 
Vessel injury by PTCA or stent strut leads to the activation of platelets and mural  
thrombus formation. The presence of vascular injury, mural thrombus, and metallic  
foreign body activates circulating neutrophils and tissue macrophages. These cells  
release cytokines and growth factors that activate smooth muscle cells (VSMCs). Up- 
regulation and expression of genes such as c-myc that regulate cell division, leading  
to cell proliferation. Production of matrix metalloproteinase is also up-regulated,  
leading to remodeling of the extra-cellular matrix, and initiating smooth muscle cell  
migration. The end result of this cascade of events is the uncontrolled proliferation of  
VSMCs around the vessel intima and the deposition of extra-cellular matrix material,  
which often lead to significant luminal narrowing 3 to 6 months after PCI [1]. Until  
recently, the only effective treatment for ISR was brachytherapy which reduces target  
vessel revascularization (TVR) rates and binary restenosis rates.  
Although effective, brachytherapy has remained a technology with limited availability  
due to difficult logistic and radioactive materials. In contrast, drug-eluting stents  
containing the immunosuppressive agent (Rapamycin) and the anti-mitotic agent  
(Paclitaxel) have shown encouraging reductions in restenosis in de novo lesions,  
and possibly in ISR lesions [30]. 
 
 
1.2. Definitions of Restenosis: 
 
When considering restenosis, three different aspects can be detected. First,  
 
histological restenosis refers to the process that occurs at the cellular level within  
 
the vessel. The second aspect is angiographic restenosis, which can be measured  
 
either by visual inspection of the angiography or by quantitative coronary  
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angiography (QCA). Finally, clinical restenosis refers to the occurrence of clinical  
 
events related to restenosis leading to symptoms or ischemia and accordingly to  
 
symptom-or ischemia-driven repeat revascularization of the vessel that was initially  
 
treated [60]. 
 
1.2.1. Angiographic Restsnosis:  
Over the last two decades, many definitions for angiographic restenosis have been  
used. Several of those are listed in (Table-1). The common definition is diameter  
stenosis (DS%) > 50% at follow-up, which was based on early studies showing  
impaired coronary flow reserve in such lesions [60]. 
 
Table-1. Angiographic Definitions of Restenosis  
 
1- EMORY: Diameter stenosis > 50% at follow-up. 
2- NHLBI I:  Increase in diameter stenosis > 30% at follow-up (compared to 
immediately after intervention). 
3- NHLBI II: Residual diameter stenosis < 50% after PTCA increasing to >70% 
at follow-up. 
4- NHLBI III: Increase in diameter stenosis at follow-up to within 10% of the 
diameter stenosis before PTCA. 
5- NHLBI IV: > 50% loss of the initial gain achieved after PTCA. 
6- THORAXCENTER IIA: > 0.72 mm loss in lumen diameter at follow-up. 
Abbreviations: NHLBI = National Heart, Lung, and Blood Institute. 
[From Safan R, Freed M. (2003): The Manual of Interventional Cardiology: Restenosis.  
3. Ed. New York, London, Toronto: Lippincott Williams & Wilkins; S. 441].       
 
 
Depending on which definition is chosen, restenosis rates can vary widely (Figure-1).  
 
As shown in Figure-1, no two definitions can completely encompass the restenotic  
 
process as measured by angiography.  
 
Studies by Serruys and Nobuyoshi performed in the late 1980s unequivocally  
 
confirmed that angiographic restenosis tends to develop between 2 and 6 months  
 
after coronary angioplasty [35, 52]. 
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Figure -1. Example of variations in outcome according to the definition of restenosis. 
The reference diameter remains constant at 3.2 mm for all examples. In example 1, 
an intermediate improvement in the MLD of 300% results in a lumen 1.6 mm (50% 
diameter stenosis). An encroachment of 0.8 mm results in a 50% decrease in MLD 
and a significant 75% residual stenosis. In example 2, further encroachment leads to 
a 75% decrease in MLD (88% diameter stenosis) and recurrent angina. Restenosis 
occurs in both cases if either definition A (Def. A > 50% diameter stenosis at follow-
up) or definition B (Def. B > 0.72 mm decrease in MLD from postoperative to follow-
up) is used. In example 3, a 600% improvement in MLD and the same amount of 
encroachment during follow-up as in example 1 results in an MLD at follow-up of 1.6 
mm (50% diameter stenosis). Restenosis occurs according to Def. B, because a 
decrease of 0.8 mm in MLD is present, but not if Def. A is used in example 4, the 
initially excellent results are maintained with the absence of restenosis either 
definition. 
[From Topol EJ. (1999): Textbook of Interventional Cardiology. 3. Ed. Philadelphia, London, 
Toronto: W.B.Saunders Company; S. 382]. 
 
1.2.2. Comparative Measurements:   
Important insights into understanding mechanisms of restenosis come from the  
 
relationship between lumen diameter at baseline, immediately after intervention, and  
 
during follow-up, expressed as acute gain and late loss (Figure-2).  
Acute gain, defined as the difference in lumen diameter before and immediately  
after intervention, is due to plaque removal and/or arterial expansion. Late loss,  
defined as the difference in lumen diameter after intervention and at follow-up,  
reflects the net effects of intimal hyperplasia, elastic recoil, and vascular remodeling.  
Several studies have shown that the relationship between acute gain and late loss is  
constant irrespective of the device. For every 1 mm acute gain in lumen diameter, 0.5  
mm is lost over 3-6 months (i. e, 50% of the initial gain is lost). Loss index is the  
ratio of late loss to acute gain a typical loss index is 0.5 [60]. 
 
 
1.3. Mechanisms of In-Stent Restenosis (ISR): 
Over-distention of the diseased vessel causes endothelial disruption, internal elastic  
lamina fracture, and medial dissection. Lumen enlargement is caused by  
a combination of plaque reduction (compression/ embolisation), axial plaque  
redistribution towards the proximal and distal segments outside the stent, plaque  
extrusion, and vessel expansion. Many processes then contribute to restenosis [30]. 
 
1.3.1. Arterial Remodeling: 
 
Negative remodeling is a major cause of human angioplasty restenosis, where > 40%  
 
of specimens retrieved at necropsy shown no evidence of neointima formation.  
 
Intravascular ultrasound studies also show that remodeling causes between two  
 
thirds and three quarters of the lumen loss in restenosis lesions. Although remodeling  
 
is largely negated by stenting, the mechanisms that contribute to remodeling are  
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unknown, or whether remodeling represents primarily a medial or adventitial  
 
response to injury [30]. 
 
 
 
                Loss Index = 0.28 mm / 0.75 mm = 0.37 
                                  
 
                                  
                         
 
                                                                                     Late loss = 0.28 
               mm          Acute gain = 0.75                                                              
 
                                                                                                                    
 
 
 
 
 
                                        MLD                  MLD                  MLD 
                                    
                                        MLD                  MLD                 MLD             
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1.03 
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Figure-2. Continuous indices (acute gain, late loss, net gain, and loss index) related 
to the minimum lumen diameter (MLD) of the coronary vessel. These indices allow 
the sensitive, objective evaluation of serial changes in vascular dimensions after 
PTCA.  
[From Kuntz RE, Safan RD, Levine MJ, et al. (1992): Novel approach to the analysis of 
restenosis after the use of three new coronary devices. J Am Coll Cardiol 19, 1493-1499].  
 
 
 
1.3.2. Thrombus Formation:  
Angiography or stenting causes endothelial denudation and induces medial  
dissection. The consequent exposure of sub-intimal components such as collagen,  
von Willebrand factor, fibronectin, and laminin causes platelet adhesion and  
aggregation. Fibrin and platelet are deposited on stent struts early after implantation.  
The association of fibrin and platelets with neointimal accumulation and extensive  
neovascularization at ISR sites suggests that organization of mural thrombus  
promotes ISR [30]. 
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1.3.3. Neointimal Proliferation:  
Arterial injury induces vascular smooth muscle cell (VSMC) proliferation and  
migration due to: 1- mechanical stretch, IEL rupture, and medial dissection,  
2- endothelial denudation with exposure to circulating mitogens such as angiotensin  
II and plasmin, and 3- release of mitogens and cytokines from platelets, endothelial  
cells, VSMCs, and inflammatory cells. VSMCs are normally in the quiescent (G0)  
phase of the cell cycle. In animal models, injury induces medial and then intimal cell  
cycle entry, following a wave of immediate early gene expression. Cells undergo  
either cell proliferation or migration or both, with subsequent synthesis of extracellular  
matrix and collagen, resulting in neointima formation [30]. Neointima formation is the  
major cause of ISR.  
Neointima increases up to three months after procedure, with little change to six  
 
months, and a gradual reduction between six months and three years.  
 
However, the role of cell proliferation within the neointima remains controversial. Cell  
 
proliferation is low in specimens retrieved from ISR sites, although higher ISR versus  
 
angioplasty restenosis sites. Although neointima formation after stenting is  
 
associated with medial disruption (extent of injury),  proliferation does not correlate  
 
with time of injury. In contrast, most proliferating cells are located deep, adjacent to  
 
stent struts, suggesting that proliferation is a chronic low-grade reaction to the stent 
[14, 64]. 
 
Importantly, the restenotic lesion after angioplasty or stenting is hypocellular  
 
compared with primary plaques, consisting of collagen and matrix proteoglycans  
 
produced by limited VSMCs. Indeed, cells comprise only 11% of the tissue mass in  
 
human post-angioplasty neointima. ISR also consists of matrix proteoglycans and  
 
collagen, with decreasing cellularity and increasing matrix as ISR develops. This lack  
 
of VSMC proliferation in ISR clearly may reduce the expected benefit of treatment  
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aimed solely at cell proliferation, compared with those that additionally alter matrix  
 
synthesis. Neointima formation within a stent also results from mechanisms, such as  
 
axial movement of primary plaque displaced to adjacent artery segment by the  
 
original procedure. Although this may represent VSMC migration, true VSMC 
 
migration from the media or adventitia adjacent to the angioplasty site analogous to  
 
that seen in animal models has not been conclusively demonstrated in humans [30].  
Vascular smooth muscle cells exhibit several growth responses to agonist that  
 
regulate their function including proliferation (hyperplasia with an increase in  
 
cell number), Hypertrophy (an increase in cell size without change in DNA  
 
content), end-reduplication (an increase in DNA content and usually size), and  
 
apoptosis. Both autocrine growth mechanisms (in which the individual cell  
 
synthesizes and/or secretes a substance that stimulates the same cell type to  
 
undergo a growth response) and paracrine growth mechanisms (in which the  
 
individual cells responding to the growth factor synthesize and /or secrete  
 
a substance that stimulates neighboring cells of another cell type) are important  
 
in VSMC growth. In many situations, autocrine and paracrine growth  
 
mechanisms occur simultaneously [7]. 
 
1.3.4. Inflammation: 
 
Porcine and non-primate models of injury show a robust inflammatory reaction to  
 
injury, with early mononuclear cell infiltration from the lumen into the thrombus.  
 
Monocytes secrete fibrinolytic enzymes, which may remodel or resorb the thrombus.  
 
Human stented arteries also show acute inflammation early after implantation,  
 
especially when stenting is associated with medial injury or lipid core penetration,  
 
and restenosis is associated with core penetration and inflammation. Indeed, some  
 
inflammatory cells (predominantly macrophages) are found at all stages of stent  
 
stenosis. As described above, resolution of inflammation may therefore play an  
 
 8
important part in restenosis, in particular via fibrosis and resultant scar contraction of  
 
both the adventitia and media [30]. 
 
 
1.4.  Angiographic Patterns of In-Stent Restenosis: 
 
One classification during the Palmaz-Schatz stent era considered stent restenosis as  
 
focal (lesion length < 10 mm) or diffuse. Focal lesions accounted for 42% of stent  
 
restenosis and generally had favorable outcomes after repeat intervention, including  
 
late target lesion revascularization (TLR) in 19%. Focal lesion were further classified  
 
as articulation or gap lesions (reflecting widespread use of the Palmaz-Schatz  
 
stent), margin lesion at the stent edge, focal lesions in the body of the stent, or  
 
short, multifocal lesions (Figure-3). Diffuse lesions were classified as in-stent- 
 
lesion in 22% (repeat TLR 35%), diffuse proliferative lesions extending beyond the  
 
stent margins in 30% (repeat TLR 50%), or total occlusion in 6% (repeat TLR 83%) 
[32].          
 
 
1.5.  Predictors of Restenosis:  
 
Predictive factors for restenosis can be divided into three general categories.  
 
Patient-related factors are characteristic of the patient, thereby generally affecting  
 
the risk of restenosis in all lesions. Lesion-related factors are characteristic unique  
 
to each lesion, which should affect the risk of restenosis independently, even for  
 
multiple lesions within the same patient. Procedure-related factors comprise  
 
methods used in the procedure itself, such as the therapies used during the  
 
procedure and the method used to reduce the stenosis (Table-2). 
 
Most notorious are aorto-ostial lesions, chronic total occlusion, and diabetes. 
 
Recently, baseline positive remodeling – enlargement of the external elastic  
 
membrane at the target lesion by IVUS – was identified as an independent predictor  
 
of clinical restenosis after PTCA and atherectomy [45]. 
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                                                             Articulation or Gap 
 
 
 
                                                             Margin 
                                                                                                               Focal Lesion,                                          
                                                                                                               42% of ISR, 
                                                             Focal Body                                TLR 19%         
                                                                                                                                                                              
 
                                              
                                                    Multifocal 
                                                   
                                                          
                                                           
                                                            Intra-stent, 22% of ISR, TLR 35% 
 
    
 
                                                  Proliferative, 30% of ISR, TLR 50% 
 
 
 
                                                 Total Occlusion, 6% of ISR, TLR 83% 
                                                
 
Figure-3. Patterns of in-stent restenosis. ISR = In-Stent Restenosis, TRL = Target 
Lesion Revascularization at 1 year.  
[From Mehran R, Dangas G, Abizaid AS, et al. (1999): Angiographic patterns of in-stent 
restenosis. Circulation  100, 1872-1878]. 
 
 
The strongest predictors of stent restenosis are the pattern of restenosis, lesion  
 
length, diabetes, total plaque burden, and final lumen cross-sectional area after  
 
stenting by IVUS. The number and length of stents reflect total plaque burden, and  
 
are important predictors of stent restenosis. However, the presence of overlapping  
 
stents is not a predictor of restenosis (Table-3 [45].  
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Table-2. Risk factors for restenosis. 
 
 Yes Maybe No 
 
Patient Factors: 
-Variant angina 
-Recent onset angina < 2-6 m 
-Unstable angina 
-IDDM 
-Chronic dialysis 
-Smoking 
-Primary PTCA in acute MI 
-Hypercholesterolemia 
-Male gender 
-Previous MI 
-Hypertension 
-Age 
-Previous restenosis 
 
 
x 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
X 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
X 
X 
 
Lesional Factors: 
-Long lesion > 20 mm 
-Multivessel / Multilesional 
-SVG (proximal and body) 
-Chronic total occlusion 
-Collaterals to dilated vessel 
-Ostial stenosis 
-Angulation > 45 
-LAD stenosis 
-Eccentricity 
-Calcification 
-Bifurcation lesion 
-Thrombus 
-Proximal location 
-LIMA 
-SVG (distal anastomosis) 
 
 
 
X 
X 
X 
X 
X 
X 
x 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
X 
X 
X 
X 
x 
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Procedural Factors: 
-Positive remodeling 
-Pressure gradient > 20 mmHg 
-Residual stenosis > 30% 
-No dissection present 
-Balloon inflation variable 
- Number of inflation 
- Inflation time 
- Maximum inflation pressure 
- Balloon Material 
- Inflation technique 
 
 
X 
X 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
X 
X 
X 
X 
X 
 
[From Safan R, Freed MS (2003): The Manual of Interventional Cardiology: Restenosis.  
3. Ed. New York, London, Toronto: Lippincott Williams & Wilkins; S. 445]. 
 
Table-3. Predictors of stent restenosis. 
 
 
Major: 
    Pattern of restenosis. 
    Lesion length. 
    Diabetes mellitus. 
Minor: 
    Final post-procedure lumen dimensions. 
    Total plaque burden. 
 
[From Safan R, Freed MS (2003): The Manual of Interventional Cardiology: Restenosis. 3. Ed. 
New York, London, Toronto: Lippincott Williams & Wilkins. S; 451]. 
 
 
1.6.  Prevention of Restenosis: 
 
1.6.1.  Prevention of restenosis after PTCA: 
 
A-Pharmacological Interventions [45]: Over the last decade, there have been  
 
numerous clinical trials of fish oil, corticosteroids, cytostatic agents, calcium channel  
 
blockers, lipid lowering agents, ACE inhibitors, low-molecular-weight heparin,  
 
antioxidants, and somatostatin analogues. One metanalysis suggest that calcium  
 
channel blockers and fish oil had beneficial effects on restenosis after PTCA (Figure- 
 
4). However, the randomized CART trial did not demonstrate a benefit for fish oil,  
 
and initial excitement for calcium channel blockers was tempered by negative  
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reports from several randomized trials. Amilodipin (10 mg/d for 2 weeks prior and 4  
 
weeks after PTCA) decreased ischemic complications at 4 months but failed to  
 
reduce restenosis in the randomized CAPARES trail. Small randomized trials of  
 
cilostazol, phosphodiesterase III inhibitor used for claudication, have shown  
 
reductions in restenosis after PTCA and stenting, further trails are pending. HMG-Co- 
 
A reductase inhibitors (Statins) have several potential mechanisms of action that  
 
could decrease restenosis, although studies thus far have been disappointing. Two  
 
randomized trials suggest that abciximab and angiopeptin (Somatostatin analog)  
 
significantly decreased clinical restenosis after PTCA, however, quantitative  
 
volumetric ultrasound analysis after stenting failed to show a reduction in initial  
 
hyperplasia with abciximab, and there was no difference in angiographic restenosis  
 
in the angiopeptin trial. Probucol, given one month prior to PTCA and continued for  
 
at least 6 months, showed benefit in two randomized studies, but pretreatment for  
 
one month is impractical in most patients. Data from TREAT and TREAT-2 suggest  
 
a possible benefit effect for tranilast after angioplasty. Despite initial promise, trapidil  
 
failed to decrease restenosis in the randomized TRAPIST study. Trials of local  
 
delivery of alcohol and other anti-proliferatives show early promise, but to date, no  
 
pharmacologic therapy has clearly been shown to reduce restnosis. Because of the  
 
differing mechanisms of restenosis after PTCA and stenting, conclusions of efficacy  
 
after PTCA do not necessarily apply to stenting [45]. 
 
B-Mechanical Interventions [44]: The stent is the only device that has been shown  
 
to reduce the incidence of restenosis compared to PTCA. Randomized trials  
 
(STRESS, BENESTENT) have conclusively demonstrated a decrease in restenosis  
 
for de novo lesions in native coronary arteries. In addition, multiple observational  
 
studies strongly suggest lower restenosis rates for stents in saphenous vein grafts.  
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Figure-4. Metanalysis of clinical restenosis trails. Restenosis as defined a follow-up 
diameter stenosis > 50% (odds ratio and 95% confidence intervals). Data entries < 1 
indicate benefit for restenosis  
[From Safan R, Freed MS (2003): The Manual of Interventional Cardiology. New York, London, 
Toronto: Lippincott Williams & Wilkins. S; 448]. 
 
 
Results of the randomized SAVED trial (Stenting or Angiography in Vein Graft  
 
Disease) found that stents reduced clinical (but not angiographic) restenosis when  
 
compared to PTCA alone. Other atheroablative devices have been disappointing for  
 
preventing restenosis. In ERBAC, despite a larger post-procedural lumen diameter,  
 
restenosis rates were higher after Rotablator and excimer laser compared to PTCA.  
 
Studies of directional atherectomy (OARS, BOAT) reported less angiographic  
 
restenosis vessel revascularization or major adverse cardiac events. 
 
C-Radiation Therapy [45]: Limited data suggest a potential role for radiation therapy  
 
in the prevention of restenosis following balloon angioplasty in previously untreated  
 
coronary arteries. Beta-radiation reduced target lesion revascularization (6% vs.  
 
24%, P < 0.05) and restenosis (8% vs. 39%, P = 0.012) in PREVENT and low  
 
restenosis rates (15% and 4%) were achieved in two other studies. In a dose ranging  
 
study of beta-radiation after PTCA (without stents), restenosis rates after 9-Gy,  
 14
15-Gy, and 18 Gy were 28,1%, 16,7%, and 3,9% respectively. Patients receiving a  
 
stent had more thrombosis or late occlusion than patients treated by PTCA alone  
 
(14,3% vs. 3,3%). Results of other randomized trails are pending.  
 
1.6.2. Management of restenosis after PTCA:  
 
The management of patients with restenosis depends on patient characteristics,  
 
myocardium at risk, lesion morphology, extent of coexisting coronary artery disease,  
 
and LV function. Repeat PTCA can be performed with high procedural success  
 
> 95% and low complication rates < 3-5%, and is frequently the procedural of choice  
 
for focal restenosis after stenting. Early registry data suggested higher restenosis  
 
rates for stenting of restenostic lesions compared to de novo lesions, which has been  
 
confirmed in late studies. More recently, however, compared to patients with  
 
restenotic lesions treated by PTCA, those treated by stenting had fewer late cardiac  
 
events (4,8% vs. 20%). Directional atherectomy can be used to treat restenosis  
 
after PTCA, but restenosis rates tend to be higher for restenotic compared to de novo  
 
lesions. In a study of 1,087 restenotic lesions treated by PTCA, directional coronary  
 
atherectomy (DCA) or stents, procedural success was achieved in 94-96% despite  
 
better initial lumen enlargement for DCA and stents, in-hospital complications,  
 
recurrent restenosis, and 3-year event-free survival were similar for all 3 devices [45]. 
 
1.6.3.  Treatment of In-stent restenosis (Table-4): 
 
A-Angioplasty, Debulking, and Restenting: IVUS studies demonstrated that  
 
PTCA for stent restenosis provided additional stent expansion and tissue extrusion  
 
out of the stent, accounting for 56% and 44% of net gain, respectively. PTCA did not  
 
achieve the same dimensions as original stent because of re-intrusion of intimal  
 
tissue. The combination of debulking (Rotablator, DCA, or Laser) and adjunctive  
 
PTCA may not have benefit over PTCA alone, despite initially promising results. In  
 
the large, randomized ARTIST trial, Rotablator for diffuse stent restenosis was  
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associated with higher in-lab complications, more late clinical events, and smaller  
 
dimensions at 6 months compared to PTCA alone, but in ROSTER, 6-month TLR  
 
was lower after Rotablator.  
 
A metanalysis of PTCA, DCA, Rotablator, Laser, and restenting for stent restenosis  
 
reported a 6-month TLR of 30% regardless of the device. Although IVUS studies  
 
suggest that restenting eliminates intimal reintusion associated with PTCA and other  
 
devices, this effect is not sufficient to prevent recurrent restenosis. Registries of small  
 
numbers of patients with in-stent restenosis treated by drug-eluting stents indicate  
 
excellent results using Sirolimus- or Paclitaxel-eluting stents [45]. 
 
B- Ionizing Radiation: At the present time, no pharmacologic or mechanical  
 
intervention can reliably treat stent restenosis. However, brachytherapy holds  
 
real promise for inhibiting intimal proliferation and decreasing the incidence of  
 
stent restenosis [45]. 
 
C – Drug eluting Stents: I will discuss it in details in the next chapter. 
 
 
Table-4. Treatment strategies for stent restenosis. 
 
Technique Comment 
 
Mechanical Approaches 
 
- PTCA 
 
 
- Debulking (DCA; 
Rotablator, Laser) 
- Stenting 
 
      -    Cutting Balloon 
 
 
 
 
- Success rates exceed 90%, restenosis rates vary from 
30-80% depending on pattern of stent restenosis and 
nature of target lesion. 
- Despite initial enthusiasm, randomized  
 trials show no benefit compared to PTCA. 
- Achieves the best immediate angiographic results, 
long-term outcomes are uncertain. 
- May facilitate immediate lumen enlargement but 
further study is needed. 
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Pharmacologic Approaches 
 
- Anti-sense DNA 
- Abciximab 
- Trapidil 
- Tranilast 
 
 
 
 
- No benefit (ITALICS trial). 
- No benefit (ERASER trial). 
- TRAPIST trial pending. 
- Trials pending. 
 
 
Brachytherapy 
  
Shows the most promise for inhibition of intimal 
proliferation, efficacy of beta- and gamma-radiation 
are established. Residual issues include edge effect, 
delayed thrombosis, and unknown late effects. 
[From Safan R, Freed MS (2003): The Manual of Interventional Cardiology: Restenosis. 3. Ed. 
New York, London, Toronto: Lippincott Williams & Wilkins. S; 452]. 
 
 
1.7.  Coated Stents for the Prevention of Restenosis: 
 
Increasing focus has recently been directed towards the different parameters of drug- 
 
eluting stents- stent design, stent coating, and drug selection- and the manner in  
 
which each of these elements may affect the function of the stents. The final  
 
parameter that bears consideration in complete evaluation of drug-eluting stents is  
 
the disease state of the target vessel.   
 
Several specific characteristics of design may affect restenosis, although design  
 
optimization often presents a choice between acute procedural success and long- 
 
term biological stability. The influence of design parameters such as strut thickness  
 
and cell configuration is described [41,42]. 
 
1.7.1.  Stent design: 
 
Development in stent strut configuration, strut thickness, and delivery-balloon  
 
technology have resulted in important procedural attributes, including reduced device  
 
profiles, increased flexibility and conformability, and fluoroscopic visibility. The same  
 
refinements that have led metal-stent design to this level have also limited  
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restenosis, with rates from recent clinical studies in the 10%-20% range [41]. 
 
Recent clinical studies suggesting an impact of metal-stent design on coronary  
 
restenosis have a foundation in several animal studies that established a link  
 
between design and depth of injury, and subsequent neointimal thickening or  
 
experimental restenosis [41,42]. 
 
Several specific design parameters may affect restenosis, although design  
 
optimization often presents a choice between acute functionality and long-term  
 
biological stability. For example, stents with thinner struts may have less visibility but  
 
also have more favorable flow dynamics within the lumen, providing less turbulent  
 
flow and less corresponding platelet activation and inflammatory cell recruitment [40]. 
 
Current metal stents can be categorized into “closed-cell” and “open-cell”  
 
configurations. Closed-cell stents have cells whose bounded area does not change  
 
as the stent is flexed (a diamond shape is an example of a close cell), while open-cell  
 
stents have cells that grow in area as the stent is flexed (a coil spring is an example).  
 
Stent with an “open-cell” configuration tend to have greater conformability to curved  
 
segments after expansion, but therefore have greater variations in arterial surface  
 
coverage between the inner and outer curvatures of a tortuous segment than do  
 
stents with a “closed-cell” design.  
 
Similarly, stents with greater surface coverage offer greater luminal circularity,  
 
minimizing tissue growth as the vessel remodels to regain optimal flow  
 
characteristics [17], but at the same time have the potential to be rigid and non- 
 
conformable and to afford limited access to side branches. Overall, in the current era,  
 
competing aspects of stent design allow practitioners to choose stents specific to the  
 
needs and challenges of a given lesion. That is, in a straight, large vessel without  
 
involved side branches, a fairly rigid but high-surface-coverage stent can be used,  
 
whereas in a smaller vessel with tortuously or side-branches involvement, a more  
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flexible stent with larger openings between struts may be the better option, albeit the  
 
expense of lower surface coverage and perhaps slightly restenosis rates.    
 
1.7.2.  Drug Coating:  
Recently, novel local delivery systems using coated stent technologies that elute  
potent anti-proliferative agents resulted in another dramatic reduction in restenosis  
rates, with rates now less than 10% in short-term follow-up. This success has  
resulted from largely empiric selection of drug, using anti-neoplastic and  
immunosuppressant agents [49]. 
 
A general understanding of cell cycle kinetics is important for designing anti- 
 
proliferative agents to inhibit neointimal growth (desirable effect) rather than killing  
 
local cells directly (undesirable effect). The two salient cell cycle effects of drugs  
 
known since the 1960΄s are cell cycle arrest (the cytostatic effect) and cell killing  
 
(the cytotoxic effect) [48].  Many of the most potent cytotoxic agents act by  
 
damaging DNA, with cell killing or cytotoxic potential greater during S-phase when  
 
DNA synthesis occurs. Agents that block the mitotic spindle formation (during M- 
 
phase) have activity against rapidly dividing cells, as occurs during neointimal  
 
growth. Thus, knowledge of cell cycle details and the agent primary action and dose  
 
help determine when cytotoxic rather than cytostatic effects occur. This knowledge is  
 
critical to designing drug regimens that effectively inhibit cellular proliferation  
 
(cytostatic) rather than cell killing [49].  
 
Stent coating can be passive or active coating. While passive coatings serve  
 
good biocompatibility, active coatings directly influence the intima proliferation.  
 
Active coatings are generally based on the effect of drug. They are either directly  
 
bonded to the surface of the stent or trapped in the three-dimensional polymers,  
 
which act like a sponge. However, the presence of polymer itself may lead to delayed  
 
inflammation and proliferation causing restenosis. Currently there are three different  
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approaches of binding drugs to coronary stents [26,63]: 
       
1- Drug binding by means of a polymer on the surface of stent. 
        
2- Drug binding aided by inorganic stent coating.  
        
3- Direct drug binding upon the stent surface without coating. 
 
On the basis of the mechanism of action of the biological compound and its target in  
 
the restenotic process, drug-eluting stents may be generally classified as  
 
immunosuppressive, antiproliferative, anti-inflammatory, antithrombotic, and  
 
pro-healing. Some agents, such as sirolimus, may affect multiple targets in the  
 
restenotic process (Figure-5) [56].Currently, the two most successful drugs used on  
 
coated stents today are rapamycin and paclitaxel. Each is a potent proliferative  
 
inhibitor, and is cytostatic rather than cytotoxic at the concentrations used in stents.  
 
Paclitaxel at higher concentrations is cytotoxic, as evidenced by use in malignancies.  
 
To build on these first generation successes and improve drug development,  
 
critical understanding of these two agents is useful [48]. 
 
1.7.3.  Sirolimus-Eluting Stents: 
 
■ Mechanism of Action:  
 
Sirolimus (rapamycin) was discovered in a soil sample from Easter Island (known  
 
locally as Rapa Nui). A naturally occurring product that is isolated from Streptomyces  
 
hygroscopicus, sirolimus is an extremely lipophilic macrolide that was initially  
 
developed as an antifungal agent on the basis of its ability to inhibit the growth of  
 
yeast. However, sirolimus was quickly observed to have potent immunosuppressive  
 
activity in mammals, which put a halt to its development as an antibiotic.  
 
In 1988, efforts to develop sirolimus as an immunosuppressant agent were renewed.  
 
These efforts ultimately led to approval by the Food and Drug Administration (FAD)  
 
of use of sirolimus as an immunosuppressant agent in September 1999 for the  
 
prophylactic treatment of renal transplant rejection.  
 
 20
 
 
                                                Endothelial Dysfunction 
 
 
 
 
 
                          Thrombus                                                       Inflammation 
 
 
 
 
 
                                                    Growth Factors. MMP 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
Arterial 
Injury 
Estrogen 
VEGF 
Cd34-Antibody
Corticosteroid 
Tranilast 
Sirolimus 
                                                                      SMC 
                                                  S 
       Signal 
  Transduction 
  G0               G1 
                                                                    G2 
                          M                                
 
Cell Cycle
Taxol 
Taxane 
Radiation 
Angiopeptin 
Actinomycin-D
Sirolimus 
Everolimus 
ABT578 
Cyclosporine 
Tacrolimus 
Mycophenolic Acid 
C-myc Antisense 
Heparin 
Herudin 
Nitric oxide 
IIb/IIIa inhibitors 
Batimastat
 
    Cell Proliferation                                     Neointimal Formation 
 
Figure-5. Leading processes of restenosis (solid lines) and correspondent inhibitory 
(dashed lines) effects of different biological agents. MMP = Matrix Metalloproteinase, 
VEGF = Vascular Endothelial Growth Factor.  
[From Sousa JE, Serruys PW, Costa M (2003): New frontiers in cardiology: drug-eluting stents 
part I. Circulation 107, 2274-2279] 
 
Evidence emerged in the early to mid-1990s that sirolimus was a potent inhibitor of  
 
the proliferation of VSMC, and the idea that it could be used to inhibit coronary artery  
 
restenosis was hatched. Study showing that sirolimus also inhibits the migration of  
 
VSMC, providing further impetus to promote the development of the drug for the  
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prevention of both in-stent restenosis and accelerated arteriopathy after heart  
 
transplantation, because the proliferation and migration of VSMC have a central role  
 
in both of these processes [29,30]. 
 
Sirolimus, with a molecular weight of 914, is a 31-member macrocyclic lactone that is  
 
structurally similar to the anti-fungal immunosuppressant tacrolimus, a 23-member  
 
macrocyclic lactone that is also produced by a streptomyces species. Oral sirolimus  
 
has a long half-life (approximately 63 hours), is largely (about 90%) sequestrated in  
 
erythrocytes, resulting in higher concentrations in whole blood than in plasma, and is  
 
metabolized by the 3A isoform of cytochrome P-450. Its primary route of elimination  
 
is through the biliary-fecal pathway [29]. The major intracellular sirolimus receptor is  
 
a small, ubiquitous, 12-kD protein called FK506-binding protein (FKBP 12), which is  
 
a member of the immunophilin family of cytosolic binding proteins. Rapamycin-FKBP  
 
12 inhibits a kinase called the mammalian target of rapamycin (mTOR) is a large  
 
conserved member of the phosphatidylinositol kinas (PIK) related kinase family  
 
protein that regulates protein translation, cell cycle progression, and cell proliferation.  
 
mTOR is a critical and essential regulator of many second messenger pathway within  
 
eukaryotic cells.  
 
Rapamycin enters cells easily where it is bound to a specific intracellular receptor  
 
FKBP 12,  rapamycin/FKBP 12 complex is a highly specific inhibitor of mTOR  
 
(Figure-6). Growth factor activation of cells activates the kinas activity of mTOR,  
 
using a number of classical intracellular signaling systems, including PI-3 kinase and  
 
the serine theonine kinase Akt. mTOR, together with PI-3K dependent signals  
 
phophorylates down-stream effectors, the best characterized of which are p70 S6  
 
(S6K1) and 4EBP-1. S6 kinase directly phosphorylates the 40S ribosomal protein S6,  
 
which correlates with increased translation of sequences that encode components of  
 
the translational machinery.  
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Figure-6. The effect of rapamycin is mediated via binding to a specific intracellular 
receptor, FKBP 12, with subsequent inactivation of the enzyme mTOR, and reduced 
activity of mTOR targets including S6 kinase and 4EP-1  
[From Martin RB (2003): In-stent restenosis: Pathology and implications for the development of 
drug eluting stents. Heart 89, 218-224]. 
 
 
Phosphorylation of the translational repressor 4EBP-1 leads to increased cap  
 
dependent translation through eukaryotic initiation factor (eiF) 4E-F. Thus, rapamycin  
 
inhibits protein synthesis. S6 kinase also phosphorylates many other downstream  
 
proteins, such as CBP80 (functions in RNA export and spicing). Growth factor  
 
activation of cells also down-regulates the cyclin dependent kinase inhibitor (CDKI)  
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p27, in addition to increasing expressing of cyclins, predominately cyclin D and E,  
 
these events are required for transit of the G1 cell cycle restriction point controlled by  
 
the retinoblastoma protein RB (Figure-7). 
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Figure-7. Artery injury induces growth factor release, resulting in increased 
expression of CDK 2 and 4, down-regulation of p27, with resultant increased activity 
of CDK 2/cyclin E and CDK 4/cyclin D complexes. These enzymes phosphorylate 
(inactivate) pRB allowing passage of cells from G1 into S phase, with subsequent cell 
division. Rapamycin leads to failure to down-regulate p27, reduced CDK 2 and 4 
activities, and failure to inactivate RB, with subsequent arrest in G0/G1.  
[From Martin RB (2003): In-stent restenosis: Pathology and implications for the development of 
drug eluting stents. Heart  89, 218-224]. 
 
 
RB is a nuclear phosphoprotein that arrests the cells during the G1phase of the cell  
 
cycle by repressing transcription of genes required for the translation from G1 to S  
 
phase. A major cellular target of pRB is the E2F family of transcription factors.  
 
Progression of a cell through G1 and S phase requires inactivation of pRB by  
 
phosphorylation. This is carried out by cyclin-dependent kinases with their cyclin  
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partners. Binding of the pRB to the E2F transcriptional factor prevents E2F  
 
transcriptional activity. As CDK activity increases, pRB becomes more  
 
phosphorylated, resulting in the release of E2F from pRB. This entire process in  
 
turn activates the S phase genes [29, 30, 31, 38]. 
 
■ Pre-clinical Data: 
The sirolimus-eluting stent is composed of a tubular stainless steel stent, the Bx 
Velocity stent (Cordis), coated with a 5-µg-thick layer of nonerodable polymer  
blended with sirolimus in a concentration of 140 µg sirolimus/cm2 of stent. The  
 
release kinetics can be modulated in such a way that both fast-release (< 15-day  
 
drug release) and slow-release formulations (> 28-day drug release) are  
 
obtained [55]. 
 
Suzuki et al. investigated the efficacy of this agent at inhibiting neointimal  
 
hyperplasia in the porcine model [58]. Stents were coated with a nonerodable  
 
polymer containing 185 µg sirolimus (SRL), 350 µg Dexametasone (DEX), or 185 µg  
 
SRL and 350 µg DEX along with uncoated controls. Forty- seven stents (metal n=13,  
 
SRL n=13, DEX n =13, SRL and DEX n =8) were inserted in major coronary arteries  
 
of 16 pigs after overstretch injury. Histological analysis and quantitative coronary  
 
angiography (QCA)  at 28 days revealed highly significant reductions in inflammation,  
 
neointimal area, and percent area stenosis between sirolimus-coated stents and  
 
uncoated stents. There was no difference in the above variables between the stents  
 
coated only with dexamethasone and the controls. Klugherz et al. also demonstrated  
 
inhibition of neointimal hyperplasia by sirolimus-coated stents in rabbits. This  
 
inhibition appeared to be dose-dependent [1, 54]. These studies show that sirolimus- 
 
eluting stent causes a short-term reduction in neointimal hyperplasia in animal  
 
models. 
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■ Clinical Data: De Novo Lesion 
 
A - FIM Study: The First In Man (FIM) study was the first published nonrandomized  
 
study in humans to investigate stent coated with antimitotic agents. It was conducted  
 
jointly in Brazil and Europe to assess the efficacy of sirolimus-coated stents in  
 
inhibiting neointimal hyperplasia. The patients had quantitative coronary angiography  
 
(QCA) and intravascular ultrasound (IVUS) done at 4 months, with clinical follow-up  
 
at 8 months. No patients had binary restenosis shown by QCA, and all patients had  
 
< 20% diameter stenosis by IVUS. No major adverse cardiac events (MACE) had  
 
occurred by 8 months. There was also no difference in clinical or angiographic  
 
endpoints between the fast-release and slow-release formulations. The 1-year follow- 
 
up results of this cohort have also published, showing essentially unchanged QCA  
 
variables. Only 1 MACE occurred by 15-month clinical follow-up [2, 40, 56]. 
 
The combination Brazilian and European results of the FIM study show no binary  
 
restenosis and no MACE up to 12 months, suggesting that both fast-release and  
 
slow-release sirolimus-coated stent have a potent inhibitory effect on neointimal  
 
hyperplasia in humans [27, 56]. 
 
B – RAVEL Study: RAndomized study with the sirolimus-eluting VElocity balloon- 
 
expandable stent in the treatment of patients with de novo native coronary artery  
 
Lesions Trial (RAVEL), led by Marie-Claude Morice, was a natural extension of the  
 
Cypher experience. RAVEL was a double-blind randomized trial in 238 patients with  
 
simple de novo lesions in 19 clinical centers from Europe and Latin America [27,  
 
52].The primary endpoint was in-stent late luminal loss. Patients received clopidogrel  
 
or ticlopidine for 2 months. In-stent late loss was significantly lower in the sirolimus  
 
stent group (- 0.01 mm) than in the standard stent group (0.80 mm, P < 0.001). None  
 
of the patients in the sirolimus-stent group had binary restenosis, and the incidence  
 
of MACE was 5.8% in the sirolimus-stent group after 1 year. Notably, no episodes  
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of stent thrombosis occurred. This study uniquely zero percent restenosis after  
 
coronary stenting [39, 52, 55]. 
 
C – SIRIUS Study (United States): Data from the multicenter, randomized, double- 
 
blind study of the SIRolImUS-coated Bx Velocity-stent in the treatment of patients  
 
with de novo coronary artery lesions (SIRIUS) have recently been presented.  
 
Patients (n = 1058) with de novo lesions were randomized to receive sirolimus- 
 
coated stents or bare Bx Velocity stents at 53 US sites [54]. The primary endpoint  
 
was target vessel failure, which included cardiac death, myocardial infarction, or  
 
target vessel revascularization at 9 months, and secondary endpoint included patient  
 
subsets with angiographic and IVUS follow-up. The Cypher stent was safe with an  
 
overall stent thrombosis frequency of 0.04%. In these more complex patients and  
 
lesions, Cypher was still associated with striking > 90% reduction of neointimal  
 
hyperplasia within the stent assessed by IVUS. Angiographic outcomes were also  
 
markedly improved with 70 –80% reductions in late loss and restenosis [27, 29]. 
 
Clinical outcomes in SIRIUS were also markedly improved, especially the reduction  
 
in out-of-hospital TLR at 9-month follow-up. The primary endpoint, TVF, was reduced  
 
by 59%, from 21% with control bare stents to 8.6% with Cypher stents. 
 
D – The New (E + C) SIRIUS (Europe and Canada) Trials: Building on the US  
SIRIUS experience, 2 additional clinical trials were simultaneously begun in Europe  
(E-SIRIUS) and Canada (C-SIRIUS). The E-SIRIUS study involved 352 patients from  
35 European sites. The C-SIRIUS study involved 100 patients from 8 sites.  
Both E-SIRIUS and C-SIRIUS were double-blinded, randomized clinical trials 
comparing the Cypher stent vs. bare stent controls and both had identical inclusion  
criteria and follow-up endpoints [27]. In some respects the New SIRIUS patients were  
more complex than the US SIRIUS patients, with smaller vessels and longer lesions  
treated (Table-5).  
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Despite the more complex lesions in New SIRIUS, the 8-month angiographic  
outcomes (late loss and restenosis) and the 9-month clinical outcomes (TLR, TVR,  
TVF, and MACE) showed even greater improvement with Cypher compared  
with control bare stents [27]. 
Table-5. Comparison of study variables. 
From Leon MB, Abiziad A, Moses JW (2003): The cypher stent: A new gold standard in the 
treatment of coronary artery disease. New York: Johnson & Johnson company; S. 45]. 
 
 
US SIRIUS 
     (n=1058) 
New SIRIUS 
(n=452) 
 
Diabetes (%) 
Reference Diameter (mm) 
Lesion Length (mm) 
Stent/Lesion Length Ratio 
 
26.4 
2.80 
14.4 
1.6 
 
23.3 
2.57 
14.7 
1.7 
 
■ Clinical Data: In-Stent Restenosis   
 
The in-stent resetnosis registry involved 41 patients treated in Brazil (n=25) and in  
 
the Netherlands (n=16). This was an open-lable safety study involving only patients  
 
with single-vessel in-stent restenotic lesions. The protocol allowed the implantation of  
 
up to 2 Cypher stents. In the Brazilian cohort, all vessels were patent at the time of  
 
12-month follow-up angiography. Late loss averaged 0.36 ± 0.46 mm in-stent and  
 
0.16 ± 0.42 mm in-lesion. One of the 25 patients developed in-stent restenosis by  
 
1-year follow-up. There were no deaths, stent thrombosis, or repeat  
 
revascularization. The Rotterdam cohort included a more complex group of patients.  
 
In this group, 19% of the patients had previous brachytherapy failure, and 1 heart  
 
transplantation was treated. There were 2 deaths, 1 late thrombosis, 1 vessel  
 
occlusion, and 2 in-lesion restenosis [1] 
 
1.7.4.  Paclitaxel-Eluting Stents: 
 
■ Mechanism of Action:  
 
Paclitaxel was isolated from the bark of the Pacific Yew, Taxus brevifolia, in 1967  
 
by U.S. National Cancer Institute (NCI) in an effort to screen naturally occurring anti- 
 
neoplastic agents. Interest in this compound was accelerated once its unique  
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mechanism of action was characterized and the potential for this drug to inhibit  
 
cellular hyperplasia was postulated. Paclitaxel was introduced as the active  
 
ingredient to Taxol, one of the most successful chemotherapeutic agents to date [21,  
 
45].  Paclitaxel has a unique mechanism of action differentiating it from other micro- 
 
tubular agents in that it promotes the assembly (polymerization) of tubulin into stable  
 
microtubules. Cells treated with paclitaxel will form unusually stable microtubules,  
 
which in turn stabilize the micro-tubular dependent activities of cell. Micro-tubules  
 
reside in the cytoplasm of all eukaryotic cells contributing to make-up of the  
 
cytoskeleton. Micro-tubules only formed when their function is elicited, otherwise they  
 
reside  
 
in the cytoplasm as sub-units called tubulin. Tubulin and micro-tubules exit in  
 
a dynamic equilibrium shifting from one state to the other depending on cellular  
 
needs [4, 44, 45]. 
 
                                                                                           Paclitaxel 
                                                     Polymerization                     
                          Tubulin                                                         Micro-tubules  
                                                    
                                               Depolymerization 
                                                                                                                                   
Micro-tubules are necessary for the function and structure of normal active cells, and  
 
are best known for their contribution to the mitotic spindle during mitosis. They play  
 
an active role in the cell cytoplasm to facilitate cell shape, cell movement and  
 
intracellular transport. More specifically, micro-tubules are essential to: 
 
              1- Cellular division.  
 
              2- Cell motility / migration. 
 
              3- Intracellular signaling (signal transduction). 
 
               4- Extra-cellular secretary processes. 
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Micro-tubules disassembly is required for G2 transition into M phase, the drug thus  
 
blocks cell proliferation in G2/M. Paclitaxel has shown a number of effects including:  
 
reduction of inflammation, interference with cell migration, anti-proliferative,  
 
apoptotic, and necrotic effects on cells depending on the dose delivered [20, 44].  
 
This may be most easily depicted in Figure-8. Several researchers have noted the  
 
different effects of paclitaxel on cell lines in a dose dependent fashion. Belotti et al.  
 
[5] noted the inhibition of cell migration at lower paclitaxel concentration (10-900 fold)  
 
than those required to affect cell proliferation. Carbal et al. [4] found that different cell  
 
types were more sensitive to paclitaxel than others. They theorized that cells with  
 
high levels of polymerized tubulin, such as macrophages, would be more sensitive to  
 
paclitaxel than other cells. They theorized that this maybe the mechanism by which  
 
inflammatory cells (macrophages) and SMCs are more sensitive to paclitaxel than  
 
ECs. 
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Figure-8. Dose-dependent effects of Paclitaxel. EC = Endothelial Cell,  
SMC = Smooth Muscle Cell.  
[From Carbal et al. (2002): Impact of Paclitaxel on cellular viability. Bosten Scientific 
Corporation]. 
 
■ Pre-clinical Data:  
 
Unlike other anti-mitotic agents, paclitaxel shifts the cytoskeleton equilibrium  
 
toward assembly, leading to reduced vascular cell proliferation, migration, and  
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signal transduction. Paclitaxel is highly lipophilic, resulting in a rapid cellular uptake  
 
and  long-lasting effect in the cell [54]. Encouraging results have been reported in  
 
several animal studies investigating paclitaxel-coated stents. These studies have  
 
demonstrated reduction of neointimal hyperplasia of up to 60% when compared with  
 
controls in the rabbit iliac artery and porcine coronary artery models. The inhibitory  
 
effect appears to be dose-dependent. However, arteries treated with paclitaxel  
 
showed incomplete healing, late persistence of large number of macrophages, and  
 
fibrin deposition [25]. 
 
Similar findings were observed with a stent platform coated with cross-linked  
 
biodegradable polymer (chondrition sulfate and gelatin) and 42.0, 20.2, 8.6, or 1.5 µg  
 
of paclitaxel in rabbit iliac arteries [13, 56]. 
 
■ Clinical Data: Polymer-Based Paclitaxel-Eluting Stents 
A series of clinical trials (TAXUS I through VI) have been designed to test the  
feasibility and effectiveness of polymer-based Paclitaxel-eluting stents in a variety of  
clinical settings [56]. 
 
1 – TAXUS I:  The TAXUS I trial was the first in-human experience evaluating safety  
 
and feasibility of the TAXUS NIRx stent system – loaded with 85 µg of paclitaxel (1.0  
 
µg/mm2) - compared with bare NIR stents (control) (Bosten Scientific Corp) for the  
 
treatment of coronary lesions. This trial was a prospective, double-blind, three-center  
 
study randomizing 61 patients with de novo lesion (≤ 12 mm) to receive TAXUS  
 
(n=31) versus control (n=30) stents (diameter 3.0 or 3.5 mm). The 30-day major  
 
adverse cardiac event (MACE) rate was 0% in both groups (P = NS). No stent  
 
thromboses were reported at 1, 6, 9, or 12 months. At 12 months, the MACE rate  
 
was 3% (1 event) in the TAXUS group and 10% (4 events in 3 patients) in control  
 
group(P = NS) (Table-17). Six-month angiographic restenosis rates were 0% for  
 
TAXUS vs. 10% for control (P = NS). There were significant improvements in MLD  
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(2.60 ± 0.49 vs. 2.19 ± 0.65 mm), DS (13.56 ± 11.77 vs. 27.23 ± 16.69), and late loss  
 
(0.36 ± 0.48 vs. 0.71± 0.48 mm) in the TAXUS group (all P < 0.01) [18]. No evidence  
 
of edge restenosis was seen in either group. Intravascular ultrasound analysis  
 
showed significant improvement in normalized neointimal hyperplasia in the TAXUS  
 
(14.8 mm3) group compared with the control group (21.6 mm3) (P < 0.05). In this  
 
trial, the TAXUS slow-release stent was well- tolerated and showed promise for  
 
treatment of coronary lesions, with significant reduction in angiographic and  
 
intravascular measures of restenosis [19]. 
 
2 – TAXUS II:  This triple-blinded, randomized, multi-center trial tested the efficacy of  
 
2 formulations of paclitaxel-eluting NIRx Conformer stent to treat patients with short  
 
de novo coronary lesions. The study included 536 patients divided into 4 groups: 267  
 
were treated with either bare (n=136) or slow-release (SR, n=131) eluting stents,  
 
whereas 269 were treated with bare (n=134) or moderate-release (MR, n=135)  
 
eluting stents. All cohort were treated with a 15-mm NIRx Conformer Stent. All eluting  
 
stents were coated with the translute polymer loaded with 1 µg of paxlitaxel/mm2.  
 
Clopidogrel (75 mg) was administrated for 6 months. The primary endpoint was  
 
6-month percent in-stent net volume obstruction measured by IVUS. Secondary  
 
endpoints were 6-month angiographic restenosis and 6- and 12-month incidence of  
 
MACE, a composite of cardiac death, myocardial infarction, and repeat  
 
revascularization. At 6 months, percent net volume obstruction within the stent was  
 
significantly lower for TAXUS stents (7.9% SR and 7.8% MR) than for respective  
 
controls (32.2% and 20.5%; P < 0.0001 for both) (Figure-9). This corresponded with  
 
a reduction in angiographic restenosis from 17.9% to 2.3% in the SR cohort  
 
(P <0.0001) and from 20.2% to 4.7% in the MR cohort (P=0.0002). Late loss was  
 
0.31 mm (SR) and 0.30 mm (MR) in the eluting-stent groups.  
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The incidence of MACE at 12 months was significantly lower (P=0.0192) in the  
TAXUS-SR (10.9%) and TAXUS-MR (9.9%) groups than in controls (22.0% and  
21.4%, respectively), predominantly because of a significant reduction in repeat  
revascularization of the target lesion in TAXUS-treated patients [10]. 
 
 
                                                                   P < 0.0001 
                                
 
                                                      P < 0.0001 
 
 
 
 
% in-stent net 
volume obstruction                                        64%                    64% 
 
 
 
 
 
 
                                           Control            TAXUS SR       TAXUS MR 
7.85 
±9.66 
7.85
±9.87
21.89 
±17.48
                                           (n=270)               (n=131)            (n=135) 
 
Figure-9. Six-month IVUS Endpoint.  
[From Colombo A, Drzewiecki J, Banning A, et al. (2003): TAXUS II: Randomized study to 
assess the effectiveness of slow- and moderate-release polymer-based Paclitaxel-eluting 
stents for coronary artery lesions. Circulation 108, 788]. 
 
 
3 – TAXUS III:  This trial was performed to evaluate the feasibility and safety of  
 
paclitaxel-eluting stent for the treatment of in-stent restenosis (ISR) and was  
 
conducted at 2 sites in Europe, enrolling 28 patients with ISR meeting the criteria of  
 
lesion length ≤ 30 mm, 50% to 90% diameter stenosis, and vessel diameter 3.0 to 3.5  
 
mm. They were treated with one or more TAXUS NIRx paclitaxel-eluting stents.  
 
Twenty-five patients completed the angiographic follow-up at 6 months, and 17 of  
 
these underwent IVUS examination. No sub-acute stent thrombosis occurred up to  
 
12 months, but there was one late chronic total occlusion, and additional 3 patients  
 
showed angiographic restenosis. The mean late loss was 0.54 mm, with neointimal  
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hyperplasia volume of 20.3 mm3. The major adverse cardiac event rate was 29%  
 
(8 patients; 1 non-Q wave MI, 1 CABG, and 6 TLR). Of the patients with TLR,  
 
1 had restenosis in a bare stent implanted for edge dissection and 2 had  
 
restenosis in a gap between 2 paclitaxel-eluting stents. Two patients without  
 
angiographic restenosis underwent TLR as a result of the IVUS assessment at  
 
follow-up (1 incomplete apposition and 1 insufficient expansion of the stent). Overall  
 
binary restenosis rate was 16% (4 of 25) [59]. 
 
4 – TAXUS IV:  TAXUS IV, a prospective, double-blind, controlled randomized  
 
trial of 1326 patients study, was conducted to evaluate the safety and efficacy of  
 
the slow-release, polymer-eluting TAXUS stent on restenosis following coronary  
 
artery stenting. The trial enrolled 1326 patients at 73 sites. Principle inclusion  
 
criteria were de novo coronary lesions 10-28 mm long, in native coronary vessels  
 
with an RVD of 2.5 to 3.75 mm, and coverable with a single 16, 24, or 32 mm stent.  
 
The primary endpoint was 9 month TVR. An angiographic analysis was conducted at  
 
the 9-month follow-up in a subset of 732 patients. The angiographic subset was  
 
further stratified to analyze patients with medically treated diabetes (n=318), and  
 
patients with RVD < 2.5 mm (n=415). Both treatment groups were well matched for  
 
all measured baseline demographic and lesion characteristics. For the angiographic  
 
subset, mean lesion length was 14.4 mm for treatment group A and 14.4 mm for  
 
treatment group B. Baseline values for RVD were 2.76 and 2.80 mm for groups A  
 
and B respectively, as compared to post-procedure values of 2.79 and 2.83 mm.  
 
In-lesional MLD was 0.93 and 0.95 mm for groups A and B respectively at baseline.  
 
Post-procedure in-stent MLD was 2.65 and 2.67 mm and analysis segment MLD was  
 
2.26 and 2.29 mm respectively for groups A and B [12]. 
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■ Clinical Data: Non-Polymer-Based Paclitaxel-Eluting Stents 
 
1- ASPECT Trial: Asian Paclitaxel-Eluting Clinical Trial was randomized study  
 
compared Supra-G stents (Cook) directly impregnated with 2 different doses of  
 
paclitaxel (1.3 µg and 3.1 µg /mm2) versus bare metal stents.  
 
At 6-months, the angiographic parameters of percent diameter stenosis (14 ± 21%  
 
vs. 39 ± 27%) and binary restenosis (4% vs. 27%) were both decreased significantly  
 
in the high-dose group compared with the uncoated stents (P < 0.001) [34]. In-stent  
 
late loss was 0.29 mm in the high-dose group, compared with 0.57 mm in low-dose  
 
group and 1.04 mm in the bare stent group. Overall, 1-year MACE incidence and  
 
target lesion revascularization rates were similar among all groups. However, 4 of the  
 
12 patients receiving the high-dose eluting stent had stent thromboses [37]. 
 
2 – ELUTES (European Evaluation of Paclitaxel-Eluting Stent): This trial  
 
compared the V-Flex stent (Cook) loaded with 4 different doses of paclitaxel (0.2,  
 
0.7, 1.4, and 2.7 µg/mm2) versus bare metal stents for the treatment of de novo  
 
lesions. Stents were directly impregnated with paclitaxel without a polymer. Patients  
 
(n=180) were randomized evenly among the 5 groups. A dose-dependent effect on  
 
in-stent late loss was observed: 0.1 mm in the high-dose groups, and 0.7 mm in both  
 
low-dose and control groups. One-year MACE incidence was similar among groups.  
 
There were no reports of death or stent thromboses [56]. 
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2- Methods: 
 
2.1. Patient Population: 
 
This observational study was conducted in the department of Cardiology at the  
 
University of Essen, Germany. A total of 106 consecutive patients received either  
 
Cypher stent or Paclitaxel stent and underwent angiographic follow-up between Aug  
 
2002 and Feb 2004.  
 
The patients were divided into two groups (Cypher, n=54; Paclitaxel, n=52). Age of  
 
patients was 61±10 years of Cypher group versus 59 ±11 years of Paclitaxel group.  
 
The Cypher group consisted of 41 male (76%) and 13 female patients (24%),  
 
whereas Paclitaxel group consisted of 37 male (71.2%) and 15 female patients  
 
(28.8%). Lesions were either de novo lesions (Cypher, n=40; Paclitaxel, n=30) or  
 
restenotic lesions (Cypher, n=14;Paclitaxel, n=22). Patients in the Cypher group  
 
underwent angiographic follow-up after 4-10 months (6.40 ±1.47months), whereas  
 
the follow-up duration in the Paclitaxel group was 3-11 months (6.38 ± 2.43 months).  
 
There was statistical difference in follow-up duration.  
 
Patients were classified as hypertensive when they had a documented history of  
 
hypertension, used blood pressure lowering drugs, or if repeated systolic and  
 
diastolic blood pressure measurements exceeded 140/90 mmHg. Patients were  
 
classified as hypercholesterolemic if serum cholesterol values exceeded 5.2 mmol/L,  
 
or if the individual received cholesterol-lowering drugs. Patients were classified as  
 
diabetic when patient received anti-diabetic drugs, or if fasting blood glucose  
 
exceeded 6.9 mmol/L. Obesity was defined as body mass index > 25 kg/m2.   
 
A positive Family history was defined as presence of coronary artery disease in first- 
 
degree relatives of patients before 55 year of age.  
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Smoking was defined either as previous smoking or as current smoking (within the  
 
month before intervention). 
 
See figure-10 which shows study design. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primary endpoint: Angiographic DS% at follow-up. 
Angiographic endpoints:  Late loss, binary restenosis, and MLD at  
follow-up.  
Clinical endpoints: The rate of death, MI (Q-wave, and non-Q-wave), CABG, 
TLR, and TVR at follow-up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure-10. Study design. RVD: Reference vessel diameter. 
 
 
2.2. Procedure: 
Paclitaxel Stent 
(n=52) 
De Novo 
(n=40) 
ISR 
(n=14) 
Lesion Length 
(12.82 ± 2.61 mm) 
RVD 
(3.02 ± 0.49 mm) 
De Novo
(n=30) 
ISR 
(n=22)
Lesion Length 
(14.61 ± 2.83 mm) 
RVD 
(3.2 ± 0.26 mm) 
Cypher Stent 
(n=54) 
 
Selective coronary angiography was performed by the Judkins technique using  the 
 
BICOR system (Siemens, Erlangen). Following femoral sheath insertion, all patients 
 
received 10,000 IU of heparin. In addition, 0.2 mg nitroglycerin was given intra- 
 
coronary after engagement of the left main stem and the right coronary artery. At 
 
least four projections for the left coronary artery and two projections for the right 
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coronary artery were taken for optimal views. Guiding catheters were either 6F or 8F  
 
(Cordis, Miami, FL, USA). The stents used in the study were sirolimius-eluting Bx  
 
Velocity balloon-expandable stent (Cordis Corp)  in 2.5, 3.0, and 3.5 mm diameter,  
 
and V-Flex stent (Cook, Inc) in 2.5, 3.0, and 3.5 mm diameter. 
 
Standard angioplasty and stent placement were performed with a monorail 
 
technique. The stents were chosen to achieve a stent-to-artery ratio of approximately  
 
1.1:1.0.  See table-6 which shows characteristics of stents in both groups. 
 
All patients received aspirin 100 mg and clopidogrel 300 mg loading dose before the  
 
procedure. Heparin was administered during the procedure according to standard  
 
practice. After the procedure, in addition to aspirin 100 mg indefinitely, clopidogrel 75  
 
mg/d was recommended for 6 months.  
 
Table-6. Characteristics of stents in the both groups. 
 
 
Variable 
 
 
Cypher group 
(n=54) 
 
Paclitaxel group 
(n=52) 
 
P-value 
 
 
Total number of Stents 
 
One stent 
 
Two stents 
 
Three stents 
 
Stent length (mm) 
 
Stent diameter (mm) 
 
Inflation pressure (atm) 
 
Direct stenting – no (%) 
 
Post-dilatation – no (%) 
 
 
86 
 
31 
 
14 
 
9 
 
14 ± 4.8 
 
3 0 ±. 0.9 
 
16 ± 2.4 
 
36 (66.6) 
 
6 (11.1) 
 
 
82 
 
28 
 
18 
 
6 
 
17.5 ± 4.7 
 
3.10 ± 0.31 
 
15 ± 1.9 
 
30 (57.7) 
 
16 (30.7) 
 
 
0.60 
 
0.52 
 
0.32 
 
0.21 
 
0.0002 
 
0.22 
 
0.31 
 
0.26 
 
0.01 
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 2.3. Angiographic Analysis:    
     
Coronary angiograms were obtained before and after stent implantation and at follow- 
 
up. All angiograms were done and analyzed by our department of Cardiology.      
 
Quantitative coronary angiography (QCA) was performed off-line with the use of the  
 
edge detection system (Cardiiovascular measurement system, Medis medical imaging   
 
system, Leiden, the Netherlands). With this system, the mean variation in determining  
 
the absolute diameter is ≤ 0.13 mm [22]. For calibration, the contrast filled guiding  
 
catheter was used. 
 
Angiography was carried out in the same orthogonal views before and after intervention  
 
and at follow-up. All angiograms were evaluated after the administration of intracoronary 
 
nitrates. The area of interest was selected after reviewing all cine-films performed during  
 
the index procedure. The normal diameter proximal and distal to the lesion were used to  
 
interpolate the reference diameter. 
The electrocardiographic tracing was also displayed in any angiographic sequence to  
select frames in the same cardiac cycles. A diastolic frame with sharply defined edges  
without foreshortening and overlap was usually selected for quantitative coronary  
angiography. 
 
From orthogonal views, the minimal luminal diameter, the reference diameter, and the  
 
percentage of stenosis were calculated. Coronary luminal diameter and degree of  
 
stenosis were measured before and after intervention, and at follow-up. In addition,  
 
acute gain and late loss were calculated (Figure-11). 
 
Restenosis was defined as > 50% diameter steosis at follow-up. The late loss  
 
was defined as the diameter immediately after the procedure minus the diameter at  
 
follow-up.  
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Acute gain was defined as the diameter immediately after the procedure minus the  
 
reference diameter immediately before the procedure.  
 
 
                               
  
Figure-11. Example from our patients shows high-degree stenosis by using 
automated edge-detection of our quantitative coronary angiography system. 
 
 
Loss index was defined as the late loss divided by acute gain. Net gain was  
 
defined as the diameter at follow-up minus the diameter before the procedure.  
 
The target lesion (TL) was defined as the stent segment plus 5 mm proximal and  
 
5 mm distal to the edge of the stent. The vessel segment (VS) was defined as the  
 
segment bounded by side branches proximal and distal to the stent segment  
 
(Figure-12). 
 
 
2.4. Statistical Analysis 
 
Continuous variables were reported as mean ± SD. Dichotomous variables were  
 
reported as percentage with 95 percent confidence interval, comparisons were  
 
formed with a Pearson chi-square test. For comparison of continuous data, a 2-tailed  
 
Student test or a non-parametric Mann Whitney-U test was performed when appropriate.   
 
A value of P < 0.05 was considered significant. 
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Figure-12.  Vessel segment (VS) was definied as the segment bounded by side 
branches proximal (A) and distal (A`) to the stent segment. Target lesion (TL) 
encompassed the stent segment and edge segment. The length of the vessel 
covered by stent struts defined the stent segment (from B to B`). The edge 
segments encompassed the vessel 5 mm proximal (C) and distal (C`) to the stent. 
 
 
2.5. Study endpoints: 
 
The primary endpoint was the percentage stenosis at angiographic follow-up, as  
 
determined by quantitative angiographic analysis. The secondary angiographic 
 
endpoints included late loss, the rate of restenosis (defined as stenosis of more than  
 
50% of the luminal diameter), and the in-stent minimal luminal diameter (MLD).  
 
The secondary clinical endpoints included the incidence of death, the need for  
 
coronary  bypass or intervention to treat clinical ischemia due to restenosis of the target  
 
lesion, and myocardial infarction (Q-wave or non-Q-wave) due to restenosis of the target  
 
lesion. Q-wave myocardial infarction was defined by the post-procedural of new Q  
 
waves greater than 0.04 second in two contiguous leads with an increase of creatine  
 
kinase level greater than twice the upper limit of normal and a creatine kinase MB  
 
fraction greater than twice the upper limit of normal.  
 41
Non-Q-wave myocardial infarction was documented on the basis of cardiac enzyme  
 
elevation (Troponin I > 0.1 ng/ml). 
 
Target lesion revasularization (TLR) was defined as need of angioplasty or bypass  
 
surgery to treat angiographic diameter stenosis more than 50% within 5 mm proximal or  
 
5 mm distal to the stent edges.  
 
Target vessel revascularization (TVR) was defined as need to treat the lesions  
 
beyond stent segment.  
 
Target vessel failure (TVF) was defined as TVR, MI, or cardiac death not attributed to  
 
a non-target vessel. 
 
 
3- Results: 
 
3.1. Demographic and Clinical characteristics: 
 
Between August 2002 and Febraury 2004, 106 patients were enrolled: 54 in the  
 
Cypher group and 52 in the Paclitaxel group. Analysis of demographic and clinical  
 
characteristics are shown in table-7.  Figure-13 represent risk factors in both groups. 
 
 
3.2. Angiographic results: 
Forty patients (74%) in the Cypher group had de novo lesion versus 30 patients (57.7%)  
in the Paclitaxel group. The number of restenotic lesions was (Cypher, n=14 vs.  
Paclitaxel, n=22). Restenotic lesions were treated in 14 patients (Cypher) and 22  
patients (Paclitaxel). 
 
Coronary anatomy and lesion characteristics are given in table-8. 
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Table-7. Demographic and clinical characteristics of study groups. 
 
 
Variable 
 
Cypher group 
      (n=54) 
Paclitaxel group 
 (n=52) 
 
P-value 
 
 
Age – y 
 
Male – no (%) 
 
Female – no (%) 
 
Smoking – no (%) 
 
Diabetes – no (%) 
 
Hypertension – no (%) 
 
Hypercholesterolemia – no (%)
 
Obesity – no (%) 
 
Family History – no (%) 
 
Stable Angina – no (%) 
 
Unstable Angina – no (%) 
 
NSTEMI – no (%) 
 
Prior MI – no (%) 
 
Prior CABG – no (%) 
 
61±10 
 
41 (76) 
 
13 (24) 
 
26 (48.2) 
 
17 (31.5) 
 
45 (83.3) 
 
52 (96.2) 
 
18 (33.3) 
 
13 (24) 
 
48 (88.8) 
 
5 (9.2) 
 
1 (1.8) 
 
10 (18.5) 
 
11 (20.4) 
 
59±11 
 
37 (71.2) 
 
15 (28.8) 
 
15 (28.8) 
 
12 (23) 
 
52 (100) 
 
50 (96.2) 
 
19 (36.5) 
 
16 (30.7) 
 
39 (75) 
 
11 (21.1) 
 
2 (3.8) 
 
10 (19.2) 
 
7 (13.4) 
 
0.32 
 
0.47 
 
0.55 
 
0.004 
 
0.14 
 
0.31 
 
0.69 
 
0.72 
 
0.42 
 
0.14 
 
0.06 
 
0.44 
 
0.78 
 
0.12 
 
MI: Myocardial infarction, CABG: Coronary artery bypass graft. NSTEMI: Non-
ST-Segment elevation myocardial infarction.  
Plus-minus values are mean±SD, frequency (%). P-value < 0.05 considered 
significant. 
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Figure-13. Risk factors in the both groups. 
 
 
Before the procedure, lesion length was 12.82 ± 2.61 mm (Cypher) vs.14.61± 2.83 mm  
 
(Paclitaxel) (P=0.15) and reference diameter (RD) was 3.02 ± 0.49 mm (Cypher) vs.  
 
3.20 ± 0.26 mm (Paclitaxel) (P=0.20).  
Before the procedure, there was no statistical difference of MLD between the two  
 
groups (Cypher, 0.90 ± 0.45 mm vs. Paclitaxel, 0.87 ± 0.42 mm; P=0.73).  
 
After the procedure, MLD was also similar between the two groups (Cypher, 2.73 ±  
 
0.47 mm vs. Paclitaxel, 2.80 ± 0.33 mm; P=0.32). Minimal luminal diameter at  
 
follow-up was (Cypher, 2.27 ± 0.62 mm vs. Paclitaxel, 2.34 ± 0.72 mm; P=0.57)  
 
The diameter stenosis (DS%) at follow-up was (Cypher, 25.11± 18.24 vs.Paclitaxel  
 
25.90 ± 21.23; P=0.83).  
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Table-8. Characteristics of lesions in the both groups. 
 
 
 
Variable 
 
 
Cypher group 
(n=54) 
 
Paclitaxel group 
(n=52) 
  P-value 
 
 
No. of diseased vessel – no (%) 
        
1 
 
2 
 
3 
 
Target lesion – no (%) 
      
LAD 
 
LCX 
 
RCA 
 
SVG 
 
Type of lesion – no (%) 
        
De novo 
 
ISR 
 
Lesion classification – no (%) 
      
A 
 
B1 
 
B2 
 
C 
 
 
 
 
8 (14.8) 
 
31 (57.4) 
 
15 (27.7) 
 
 
 
22 (40.7) 
 
25 (46.3) 
 
6 (11.1) 
 
1 (1.8) 
 
 
 
40 (74) 
 
14 (26) 
 
 
 
5 (9.2) 
 
20 (37) 
 
19 (35.2) 
 
10 (18.5) 
 
 
 
16 (30.7) 
 
17 (32.7) 
 
19 (36.5) 
 
 
 
24 (44.4) 
 
15 (28.8) 
 
11 (21.1) 
 
2 (3.8) 
 
 
 
30 (57.7) 
 
22 (42.3) 
 
 
 
6 (11.5) 
 
17 (32.7) 
 
15 (28.8) 
 
14 (26.9) 
 
 
 
0.04 
 
0.006 
 
0.33 
 
 
 
0.62 
 
0.009 
 
0.12 
 
0.45 
 
 
 
0.06 
 
0.08 
 
 
       
0.62 
 
0.43 
 
0.38 
 
0.27 
 
LAD: Left anterior descending, LCX: Left circumflex, RCA: Right coronary artery, 
SVG: Saphenous vein graft, ISR: In-stent restenosis, F/U: Follow-up. 
Plus minus values are mean ± SD, frequency %. P < 0.05 considered significant. 
 
 
 
 
Angiographic analysis showed no significant differences of DS% before and after the  
 
procedure between two groups (70.25 ± 13.39 vs. 71.46 ± 14.27;P=0.65; 9.51 ± 9.42  
 
vs.10.40 ± 6.27; P=0.57; Cypher vs. Paclitaxel). 
 
The rate of restenosis, defined as stenosis of more than 50%, was 12.9% in Cypher  
 
group in compare with 15.3% in Paclitaxel group (P=0.65). Table-9 summarizes the  
 
angiographic measurements.  
 
Stent segment analysis revealed same late loss in both treatment groups (0.41±  
 
0.58 mm vs. 0.45 ± 0.60 mm; P=0.71; Cypher vs. Paclitaxel). In addition, there was  
 
no significant difference of acute gain between two groups (1.79 ± 0.46 mm vs.  
 
1.94 ± 0.47 mm; P=0.10; Cypher vs. Paxlitaxel). Finally, the difference of loss index  
 
between the two groups was not statistically significant (Cypher, 0.34 ± 0.38 vs.  
 
Paclitaxel, 0.29 ± 0.42; P=0.59) (Table-9). See also figures-14, 15, 16, and 17. 
 
 
3.3. Clinical events at follow-up: 
 
The Major adverse cardiac events (MACE) are summarized in Table-10. 
No patients in the both groups suffered from MI (either Q-wave or non Q-wave) at  
 
follow-up. The incidence of the death was 0% in the both groups. 
In the Cypher group, 6 patients (11.1%) underwent percutaneous coronary interventions  
(PCIs) (either brachytherapy or drug-eluting stent implantation) at follow-up because of  
high-degree in-stent restenosis (ISR) within 5 mm proximal and 5 mm distal to the stent  
edges (TLR), and 1 patient (1.8%) underwent drug-eluting stent implantation due to  
high-degree restenosis beyond the stent segment (TVR). 
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Table-9. Angiographic measurements. 
 
 
Variable 
 
 
Cypher group 
  (n=54) 
 
Paclitaxel group 
(n=52) 
 
P-value 
 
 
Lesion length (mm) 
 
Reference diameter (mm) 
 
Diameter stenosis (%) 
 
    Before 
 
    After 
 
    At F/U 
 
MLD (mm) 
 
   Before 
 
   After 
 
   At F/U 
 
Late loss (mm) 
 
Acute gain (mm) 
 
Net gain (mm) 
 
Loss index  
 
Binary restenosis-no (%) 
 
   De novo lesions 
 
   In-stent restenosis 
 
12.82 ± 2.61 
 
3.02 ± 0.49 
 
 
 
70.25 ± 13.39 
 
9.51 ± 9.42 
 
25.11± 18.24 
 
 
 
0.90 ± 0.45 
 
2.73 ± 0.47 
 
2.27 ± 0.62 
 
0.41 ± 0.58 
 
1.79 ± 0.46 
 
1.37 ± 0.57 
 
0.34 ± 0.38 
 
7 (12.9) 
 
3 (7.5) 
 
4 (28.5) 
 
14.61± 2.83 
 
3.20 ± 0.26 
 
 
 
71.46 ± 14.27 
 
10.40 ± 6.27 
 
25.90 ± 21.23 
 
 
 
0.87 ± 0.42 
 
2.80 ± 0.33 
 
2.34 ± 0.72 
 
0.45 ± 0.60 
 
1.94 ± 0.47 
 
1.64 ± 0.84 
 
0.29 ± 0.42 
 
8 (15.3) 
 
3 (10) 
 
5 (22.7) 
 
0.15 
 
0.20 
 
 
 
0.65 
 
0.57 
 
0.83 
 
 
 
0.73 
 
0.32 
 
0.57 
 
0.71 
 
0.10 
 
0.52 
 
0.59 
 
0.65 
 
0.06 
 
0.07 
 
MLD: Minimal luminal diameter, F/U: Follow-up.  
Plus-minus values are means ± SD. P < 0.05 considered significant. 
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                                                                    P=0.57 
                      
 
                     
 
 
                        
                    
 
                     
                    
                     
                      
                                                                
                                                 
                                                      Cypher                Paclitaxel 
                                                  (n=54)                    (n=52) 
 
Figure-14. Minimal luminal diameter (MLD) at follow-up. 
 
       
 
 
                                                                  P=0.83 
 
                      
 
 
                      
 
                
                      
                      
 
 
                      
                                                    Cypher              Paclitaxel 
2.27 ± 
0.62 mm
2.34 ± 
0.72 mm
25.11± 
18.24 % 
25.90± 
21.23 %
                                                 (n=54)                  (n=52) 
 
Figure-15. Diameter stenosis (DS%) at follow-up. 
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                                              Cypher              Paclitaxel 
                                                 (n=54)                 (n=52)   
 
Figure-16. Late loss at follow-up.                  
 
 
                                                                    P=0.10 
 
 
                  
 
                  
 
       
                   
 
 
                 
 
 
                  
                                                     Cypher               Paclitaxel 
                                                (n=54)                   (n=52) 
 
Figure-17. Acute gain at follow-up. 
 
 
0.41 ± 
0.58 mm
0.45 ± 
0.60 mm
1.79 ± 
0.46 mm
1.94 ± 
0.47 mm
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In the Paclitaxel group, 6 patients (11.5%) underwent PCIs for high-degree restenosis in  
 
lesion segment (TLR), and 2 patients (3.8%) were treated either with brachytherapy or  
 
drug-eluting stent implantation due to high-degree restenosis beyond the stent edges  
 
(TVR). Coronary artery bypass graft was not performed to any patient in the both groups  
 
at follow-up. 
Two patients (3.7%) in the Cypher group had target vessel failure (TVF). The first patient  
had received a stent of a de novo lesion in segment 12 (Cypher stent was implanted in  
segments 11, 13) at 6-months follow-up, whereas the second one had undergone stent  
implantation of a de novo lesion in segment 7 distal to previously implanted Cypher stent  
at 6-month follow-up. In the Paclitaxel group, three patients (5.7%) had TVF. The first  
patient was treated with brachytherapy of in-stent restenosis (ISR) in segment 7 distal to  
the Paclitaxel stent. The second one was also treated with brachytherpay due to  
appearance of ISR in segment 6 proximal to the Paclitaxel stent, and the third one  
underwent  PTCA of ISR in segment 8 distal to the Paxlitaxel stent (Table-10). 
 
3.4. Subgroup analysis: 
We divided the lesions into de novo lesions and in-stent restenosis lesions in  
order to compare the results of the two stents. 
 
3.4.1. De Novo lesions (Cypher vs. Paclitaxel): 
 
Seventy-four percent of patients who received Cypher stent had de novo lesions   
 
compared with 57.6% of patients who received Paclitaxel stent. 
 
Before the procedure, DS% in the first group (69.75 ± 13.67%) and DS% in the second  
 
group (71.3 ± 15.96% ) were similar (P=0.66). After the procedure, there was no  
 
significant difference of DS% between both groups (9.27 ± 9.27% vs. 10.5 ± 5.78%;  
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P=0.52; Cypher vs. Paclitaxel). 
 
Table-10. Clinical events at follow-up. 
 
 
Events 
 
 
Cypher 
(n=54) 
 
Paclitaxel 
(n=52) 
 
     P-value 
 
 
Death – no (%) 
 
MI – no (%) 
 
    Q-wave 
 
    Non Q-wave 
 
TLR – no (%) 
 
   TL-CABG 
 
   TL-PCI 
 
TVR – no (%) 
 
TVF – no (%) 
 
 
0 
 
 
 
0 
 
0 
 
 
 
0 
 
6 (11.1) 
 
1 (1.8) 
 
2 (3.7) 
 
0 
 
 
 
0 
 
0 
 
 
 
0 
 
6 (11.5) 
 
2 (3.8) 
 
3 (5.7) 
 
- 
 
 
 
- 
 
- 
 
 
 
- 
 
0.78 
 
0.44 
 
0.52 
 
MI: Myocardial infarction, TLR: Target lesion revascularization, TVR: Target 
vessel revascularization, CABG: Coronary artery bypass graft,   
TVF: Target vessel failure, PCI: Pecutaneous coronary intervention. 
 
 
 
Finally, we did not find any significant difference of DS% between the two groups at  
 
follow-up (Cypher, 21.12 ±16.44% vs. Paclitaxel, 22.8 ± 19.78%; P=0.73) (Figure-18). 
 
Pre-procedural minimal luminal diameter (MLD) was similar in the both groups  
 
(0.91± 0.44 mm vs. 0.88 ± 0.49 mm; P=0.85; Cypher vs. Paclitaxel). Also, there  
 
was no significant difference of post-procedural MLD (2.70 ± 0.43 mm vs. 2.79 ±  
 
0.43 mm; P=0.33; Cypher vs. Paclitaxel). 
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                                                                P=0.73 
               
21.12 ±
16.44 %
22.60 ±
19.76 %
 
                                           Cypher                       Paclitaxel 
                                            (n=40)                           (n=30) 
 
Figure-18. Diameter stenosis (DS%) of de novo lesions at follow-up. 
 
               
Minimal luminal diameter of Cypher group at follow-up was the same as MLD of  
 
Paclitaxel group at follow-up (2.35 ± 0.56 mm vs. 2.40 ± 0.69 mm; P=0.73, respectively)  
 
(Figures-19, 20, 21).  
 
Angiographic analysis showed no differences of late loss, acute gain, loss index, as well  
 
as net gain among the patients of both groups. Binary restenosis (BR), defined as  
 
stenosis diameter more than 50%, was detected in 3 patients (7.5%) in the Cypher  
 
group compared with 3 patients (10%) in the Paclitaxel group (P=0.07).  
 
Table-11 summarized the angiographic results of de novo lesions. Clinical events  
 
including TLR, TVR, TVF, death, and MI are summarized in Table-12. 
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                                                              P=0.73                                                                                        
                                               Cypher                Paclitaxel    
2.35 ± 
0.56 mm
2.40 ± 
0.69 mm
                                                (n=40)                   (n=30) 
 
Figure-19. Minimal luminal diameter (MLD) of de novo lesions at follow-up. 
                        
                               
 
3.4.2. Restenotic lesions (Cypher vs. Paclitaxel): 
 
Fourteen patients (25.9%) in the Cypher group compared with 22 patients (42.3%)  
 
in the Paclitaxel stent had in-stent restenosis lesions.Before procedure, minimal luminal  
 
diameter (MLD) was similar between the two groups (0.87 ± 0.49 mm vs. 0.84 ± 0.32  
 
mm; P=0.84; Cypher vs. Paclitaxel). In addition, diameter stenosis (DS%) in the Cypher  
 
group (71.71± 12.95%) was the same as DS% of Paclitaxel group (71.60 ± 11.96%)  
 
(P=0.99). There was no significant difference of post-procedural DS% between the two  
 
groups (10.21 ± 10.16% vs. 10.27 ± 7.02%; P=0.98; Cypher vs. Paclitaxel). Post- 
 
procedural MLD in the Cypher group was (2.80 ± 0.58 mm), and (2.82 ± 0.30 mm) in the  
 
Paclitaxel group (P=0.92) (Figures-22, 23).  
Angiographic analysis at follow-up showed no significant difference of MLD and  
DS% between the two groups (2.03 ± 0.75 mm vs. 2.11± 0.79 mm; 36.50 ± 18.91%  
vs. 32.45 ± 24%; Cypher vs. Paclitaxel, respectively) (Figures-24, 25). 
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Figure-20. Minimal luminal diameter of de novo lesions (n=40) in the Cypher 
group. 1= MLD before, 2= MLD after, 3= MLD at follow-up. 
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Figure-21. Minimal luminal diameter of de novo lesions (n=30) in the Paclitaxel 
group. 1= MLD before, 2= MLD after, 3= MLD at follow-up. 
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Table-11. Angiographic measurements of de novo lesions. 
   
 
Variable 
 
 
Cypher 
(n=40) 
 
Paclitaxel 
(n=30) 
 
P-value 
 
 
Diameter stenosis % 
 
   Before 
 
   After 
 
   Follow-up 
 
MLD (mm) 
 
   Before 
 
   After 
 
   Follow-up 
 
Late loss (mm) 
 
Acute gain (mm) 
 
Net gain (mm) 
 
Loss index  
 
BR – no (%) 
 
 
 
 
69.75 ± 13.67 
 
9.27 ± 9.27 
 
21.12 ± 16.44 
 
 
 
0.91 ± 0.44 
 
2.70 ± 0.43 
 
2.35 ± 0.56 
 
0.33 ± 0.49 
 
1.79 ± 0.45 
 
1.44 ± 0.55 
 
0.25 ± 0.22 
 
3 (7.5) 
 
 
 
71.30 ± 15.96 
 
10.50 ± 5.78 
 
22.6 ± 19.76 
 
 
 
0.88 ± 0.49 
 
2.79 ± 0.34 
 
2.40 ± 0.69 
 
0.36 ± 0.51 
 
1.92 ± 0.52 
 
1.52 ± 0.91 
 
0.28 ± 0.50 
 
3 (10) 
 
 
 
 
0.66 
 
0.52 
 
0.73 
 
 
 
0.85 
 
0.33 
 
0.73 
 
0.78 
 
0.24 
 
0.65 
 
0.71 
 
0.07 
 
MLD: Minimal luminal diameter, BR: Binary restenosis. 
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Table-12. Clinical events at follow-up of patients with de novo lesions. 
 
 
 
Events 
 
 
Cypher 
(n=40) 
 
Paclitaxel 
(n=30) 
 
     P-value 
 
 
Death – no (%) 
 
MI – no (%) 
 
    Q-wave 
 
    Non Q-wave 
 
TLR – no (%) 
 
   TL-CABG 
 
   TL-PCI 
 
TVR – no (%) 
 
TVF – no (%) 
 
 
0 
 
 
 
0 
 
0 
 
 
 
0 
 
2 (5) 
 
0  
 
2 (5) 
 
0 
 
 
 
0 
 
0 
 
 
 
0 
 
2 (6.6) 
 
1 (3.3) 
 
2 (6.6) 
 
- 
 
 
 
- 
 
- 
 
 
 
- 
 
0.06 
 
0.04 
 
0.06 
 
MI: Myocardial infarction, TLR: Target lesion revascularization, TVR: 
Target vessel revascularization, CABG: Coronary artery bypass graft,  
TVF: Target vessel failure, PCI: Pecutaneous coronary intervention. 
P < 0.05 considered significant. 
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                                                                    P=0.59                                                                            
                                                                                                                                        
                                                        Cypher                   Paclitaxel 
                                                (n=14)                      (n=22)                                                          
 
Figure-22. Diameter stenosis (DS%) of restenotic lesions at follow-up. 
 
 
                                                                              P=0.78 
 
                                                      Cypher                 Paclitaxel 
32.45 ±
24 % 
2.03 ± 
0.75 mm
2.11 ± 
0.79 mm
36.50 ±
18.91 %
                                              (n=14)                     (n=22) 
 
 
Figure-23. Minimal luminal diameter of restenotic lesions at follow-up. 
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On the other hand, there were no significant differences of the other angiographic  
parameters (Late loss, acute gain, net gain, and Loss index). Table-13 shows the  
angiographic parameters of restenotic lesions in the both groups. 
 
 
Table-13. Angiographic parameters of restenotic lesions. 
 
 
Variable 
 
 
Cypher 
 (n=14) 
 
Paclitaxel 
(n=22) 
 
P-value 
 
 
Diameter stenosis % 
 
   Before 
 
   After 
 
   Follow-up 
 
MLD (mm) 
 
   Before 
 
   After 
 
   Follow-up 
 
Late loss (mm) 
 
Acute gain (mm) 
 
Net gain (mm) 
 
Loss index  
 
BR – no (%) 
 
 
 
 
71.71± 12.95 
 
10.21± 10.16 
 
36.5 ± 18.91 
 
 
 
0.67 ± 0.49 
 
2.80 ± 0.58 
 
2.03 ± 0.75 
 
0.76 ± 0.48 
 
1.93 ± 0.39 
 
1.17± 0.59 
 
0.41± 0.30 
 
4 (28.5) 
 
 
 
71.68 ± 11.96 
 
10.27 ± 7.02 
 
32.45 ± 24 
 
 
 
0.84 ± 0.32 
 
2.82 ± 0.30 
 
2.11± 0.79 
 
0.70 ± 0.69 
 
1.97 ± 0.41 
 
1.26 ± 0.68 
 
0.39 ± 0.36 
 
5 (22.7) 
 
 
 
0.99 
 
0.98 
 
0.59 
 
 
 
0.84 
 
0.84 
 
0.92 
 
0.78 
 
0.76 
 
0.74 
 
0.88 
 
0.07 
 
 
MLD: Minimal luminal diameter, BR: Binary restenosis. 
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Clinical events at follow-up including TLR, TVR, death, and MI were similar  
 
between the two groups. However, There was no difference in TVF between the two  
 
groups (P=0.05). Table-14 summarized the clinical events of restenotic lesions in the  
 
two groups. 
 
Table-14. Clinical events at follow-up of restenotic lesions. 
 
 
 
Events 
 
 
Cypher 
(n=14) 
 
Pxlitaxel 
(n=22) 
 
     P-value 
 
 
Death – no (%) 
 
MI – no (%) 
 
    Q-wave 
 
    Non Q-wave 
 
TLR – no (%) 
 
   TL-CABG 
 
   TL-PCI 
 
TVR – no (%) 
 
TVF – no (%) 
 
 
0 
 
 
 
0 
 
0 
 
 
 
0 
 
4 (28.5) 
 
1 (7.14)  
 
0  
 
0 
 
 
 
0 
 
0 
 
 
 
0 
 
4 (18.2) 
 
1 (4.5) 
 
1 (4.5) 
 
- 
 
 
 
- 
 
- 
 
 
 
- 
 
0.08 
 
0.09 
 
0.05 
 
MI: Myocardial infarction, TLR: Target lesion revascularization, TVR: 
Target vessel revascularization, CABG: Coronary artery bypass graft,  
TVF: Target vessel failure, PCI: Percutaneous coronary intervention. 
P < 0.05 considered significant. 
 
Figures-26, 27 represent two examples of patients who received either Sirolimus- 
 
eluting stent or Paclitaxel-eluting stent, these figures show no in-stent restenosis at  
 
6-month follow-up. 
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Figure-24. Minimal luminal diameter of restenotic lesions (n=14) in the Cypher 
group. 1= MLD before, 2= MLD after, 3= MLD at follow-up. 
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Figure-25. Minimal luminal diameter of restenotic lesions (n=22) in the Paclitaxel 
group. 1= MLD before, 2= MLD after, 3= MLD at follow-up. 
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                                A                                                           B 
 
                                                           C 
          
 
 
Figure-26. Example of patient who recieved sirolimus-eluting stent in proximal 
segment 6 of left anterior descending artery. A: before stenting, B: after, and C: at 
6-month follow-up. 
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                              A                                                       B 
 
 
                                                                   C                                                       
 
Figure-27. Example of patient who recieved paclitaxel-eluting stent in proximal 
segment 7 of left anterior decsending artery. A: before stenting, B: after, and C: at 
6-month follow-up. 
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4-Discussion: 
 
We investigated the in-stent restenosis (ISR) rate of sirolimus-eluting and paclitaxel- 
 
eluting stents. The main finding of our study is that the sirolimus-eluting and paclitaxel- 
 
eluting stents appear equally effective and safe in reducing the restenosis rate (12.9%  
 
vs.15.3%). In addition, comparison of de novo and restenotic lesions between the 2  
 
stents showed no significant difference of restenosis rates at follow-up (de novo, 7.5%  
 
vs. 10%; restenosis, 28.5% vs. 22.7%; Cypher vs. Paclitaxel).  
 
No deaths or MI were reported at follow-up. Target lesion revascularization, target  
 
vessel revascularization, and target vessel failure rates were similar between the two  
 
groups.  
 
The Cypher stent has a much better data basis, we know much more about it than  
 
about the Cook stent. Accordingly, it is important to establish that the Cook stent is not  
 
apparently inferior to the Cypher stent. Therefore, our observational study tested the  
 
efficacy and safety of the Cook stents (paclitaxel-eluting without a polymer) in  
 
comparison with the Cypher stents (sirolimus-eluting). The sirolimus-eluting stents  
 
used in this study were composed of a tubular stainless steel stent, the Bx Velocity  
 
stent (Cordis), coated with a 5-µg-thick layer of nonerodable polymer blended with  
 
sirolimus. The paclitaxel-eluting stents were V-Flex stents (Cook) impegrated directly  
 
with paclitaxel without a polymer. In contrast, The Milan DES experience compared  
 
Cypher stents with Taxus stents (polymer-based paclitaxel-eluting stent) which was  
 
presented at the American Heart Association (AHA) scientific sessions 2004 [9]. In this  
 
trial 1362 patients underwent Drug-Eluting Stent (DES) implantation – 921 received the  
 
Cypher stents and 441 patients received the Taxus stents. At 30 days, revascularization  
 
of target lesion was performed in one patient in the Cypher group versus 2 patients in  
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the Taxus group. Three patients in each group developed subacute thromboses (P=0.3).  
 
The overall MACE were similar between the both groups (Cypher, 3 patients vs. Taxus,  
 
3 patients). In the Cypher group 457 patients underwent clinical follow-up at 6 months.  
 
TLR was performed in 71 patients (15.5%), while 83 patients (18%) underwent TVR.  
 
Further, this trial compared efficacy and safety between the Cypher and Taxus stents in  
 
chronic total occlusion (CTO). Sixty-nine patients received Taxus stents, while 132  
 
patients received Cypher stents. In the Taxus arm angiographic follow-up was available  
 
in 10 (15%) of patients. MLD at follow-up was 2.92 ± 0.61 mm, and DS% was 11± 10%.  
 
Clinical follow-up was performed at 5 ± 2.9 months. Three patients (4.3%) had TLR, and  
 
3 patients (4.3%) had TVR. MACE were reported in 3 patients (4.3%). In Cypher arm  
 
angiographic follow-up was available in 49% of patients. MLD at follow-up was 1.66  
 
±1.02 mm, and DS% was 45 ± 32%. Clinical follow-up was done at 9 ± 4.4 months.  
 
Fifteen patients (11.3%) had TRL, and 18 patients (18%) had TVR. MACE were  
 
reported in 19 patients (14.4%). So what does this mean – there was no statistical  
 
difference in outcome in this preliminary, small experience.  
 
Moreover, Omar AR et al. [36] compared the Cypher and Taxus (polymer-based  
 
paclitaxel-eluting) stents in PCI of complex coronary stenoses. This trial was conducted  
 
at National University Hospital, Singapore, which was presented at scientific sessions of  
 
the American Heart Association 2003. Dr Omar reviewed outcomes of 145 patients – 58  
 
received Cypher stents and 87 received Taxus stents. Ninety-six percent  of the target  
 
lesions were de novo, while 4% had undergone previous PCI. At 30 days,  
 
revascularization of the target vessel was required in 2 patients – one in each arm – and  
 
one Taxus patient developed subacute stent thrombosis a week after the procedure.  
 
There was a trend at 30 days toward lower MACE rates in the Taxus arm than in the  
 
Cypher arm (8% vs. 15.5%), but this was not sustained at 6 months, when the rate in  
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the Taxus arm was 2.4% vs. 1.9% in the Cypher arm. Moreover, there was a statistically  
 
significant larger mean reference diameter (2.83 vs. 2.68 mm) and post-minimal luminal  
 
diameter (2.87 vs. 2.66 mm) in the Taxus arm (P<0.001). At 6 months, there was  
 
significant difference in clinical outcomes even though the patients in the Cypher arm  
 
had more complex lesions. 
 
 
Over the past decade, the use of stents has become common practice during 
 
percutaneous coronary intervention (PCI), especially after clinical trials showed  
 
evidence of decreased restenosis rates when compared with balloon angioplasty  
 
alone [6, 50]. Although stents significantly reduce restenosis when compared with  
 
balloon angioplasty, restenosis rates in patients who receive stents are still 20% to  
 
40% at 6 months [1].  
 
Recently, noval local drug delivery systems using coated stent technologies that  
 
elute potent antiproliferative agents resulted in another dramatic reduction in  
 
restenosis rates, with rates now less than 10% in short-term follow-up. This success  
 
has resulted from largely empiric selection of drugs, using anti-neoplastic and  
 
immunosuppressant agents [49]. Drug-eluting stents offer theoretical advantages  
 
over systemic pharmacologic therapy, such as higher drug concentrations at the site  
 
of stent deployment and minimal systemic side effects. Among drug-eluting stents,  
 
sirolimus and paclitaxel-eluting stents showed promise in reducing in-stent  
 
restenosis as explained above [1]. 
 
 
Our study showed no difference of diameter stenosis (DS%) at follow-up between the  
 
two groups (25.11±18.24% in the Cypher group vs. 25.90 ± 21.23% in the Paclitaxel  
 
group; P=0.83). Binary restenosis (BR), defined as stenosis > 50%, was detected in 7  
 
patients (12.9%) in the Cypher group versus 8 patients (15.3%) in the Paclitaxel  
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group (P=0.65). Minimal lumen diameter (MLD) at follow-up was similar between the  
 
two groups (Cypher, 2.27± 0.62 mm vs. Paclitaxel, 2.34 ± 0.72 mm; P=0.57). In addition,  
 
no significant difference of late loss was detected (Cypher, 0.41± 0.58 mm vs. Paclitaxel,  
 
0.45 ± 0.60 mm; P=0.71). Other angiographic parameters (acute gain, loss index, and  
 
net gain) were the same in the both groups.  
 
No patients in either group suffered from myocardial infarction during the follow-up  
 
duration or died due to cardiac cause. In addition, no one underwent bypass surgery  
 
(CABG) for revascularization of the target lesion. Six patients (11.1%) in the Cypher  
 
group treated either with brachytherapy or with drug-eluting stents due to high-degree  
 
in-stent restenosis within 5 mm proximal and 5 mm distal to the stent edges (TLR)  
 
compared with 6 patients (11.5%) of the Paclitaxel group (P=0.78). Furthermore, the  
 
difference of TVR and TVF between the two groups was not statistically significant  
 
(P=0.44, 0.52 respectively). 
 
We compared the effectiveness of both stents on de novo lesions and restenotic lesions.  
 
Diameter stenosis (DS%) at follow-up was the same either in de novo lesions subgroup  
 
(Cypher, 21.12 ±16.44% vs. Paclitaxel, 22.6 ±19.76%; P=0.73) or in restenotic lesions  
 
subgroup (Cypher, 36.5 ±18.91% vs. Paclitaxel, 32.45 ±24%; P=0.59).  Furthermore,  
 
restenosis rate in de novo lesions was similar in the both groups (7.5% vs. 10%; P=0.06;  
 
Cypher vs. Paclitaxel) as it was in restenotic lesions (28.5% vs. 22.7%; P=0.07,  
 
respectively). Other angiographic parameters were the same between the Cypher and  
 
Paclitaxel stents in the both subgroups.Overall, there was no difference in the incidence  
 
of target lesion revascularization (TLR) for both de novo lesions and restenotic lesions  
 
(de novo lesions, 5% vs. 6.6%; P=0.06, restenotic lesions, 28.5% vs. 18.2%; P=0.08,  
 
Cypher vs. Paclitaxel respectively). One patient (3.3%) who received a paclitaxel-eluting  
 
stent for the treatment of de novo lesions underwent PCI in order to treat high-degree  
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stenosis beyond the stent margins (TVR) whereas no one in the Cypher group had TVR  
 
(P=0.04). In addition, TVF was the same between Cypher and Paclitaxel stents in de  
 
novo subgroup (5% vs. 6.6%; Cypher vs. Paclitaxel respectively; P=0.06). one patient  
 
(4.5%) who received a paclitaxel-eluting stent for the treatment of in-stent restenosis  
 
(ISR) was treated with brachytherapy proximal to previously implanted drug-eluting stent  
 
(TVF) whereas no one in the Cypher group had TVF (P=0.05). Moreover, TVR was the  
 
same between Cypher and Paclitaxel stents in restenotic lesion subgroup ( 7.14% vs.  
 
4.5% respectively; P=0.09). From these results we can conclude that the Paclitaxel- 
 
eluting stents are equally effective and safe as the Sirolimus-eluting stents. 
 
 
Some limitations of our study should be noted. First, sample size was small. This is  
 
explained by the relatively infrequent use of the novel stents and the necessity to obtain  
 
a follow-up examination. However, such a comparison has – to our best knowledge –  
 
not been performed elsewhere in Germany, and it should help to increase our  
 
knowledge regarding the clinical outcome of these stents. Second, our study was  
 
observational, and patients were not randomized. It is possible that confounding factors  
 
played a role which were not accounted. Also, there were some demographic  
 
differences, which appeared, however, to be very minor. Finally, with limitations in the  
 
duration of follow-up and sample size, it is possible that differences between the groups  
 
were present but were not detected. We consider this unlikely, because neither in the  
 
angiographic parameters nor in the clinical data, trend in favor for one or the other stent  
 
system was observed. 
 
Conclusions: In this clinical observational study, we did not observe significant  
 
differences between the sirolimus-coated Cypher stent and the non-polymer paclitaxel- 
 
coated Cook stent in terms of angiographic follow-up parameters and binary restenosis  
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rate. Because our study was too small and not randomized, it does not allow statements  
 
on differences in short-term or long-term performance of the stent systems. However,  
 
the lack of substantial differences in 6-month outcome compared with the well- 
 
established sirolimus-coated Cypher stent suggest that the non-polymer paclitaxel- 
 
coated Cook stent is reasonably safe and effective. 
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5- Summary: 
 
The aim of the current study was to compare the restenosis rate between sirolimus- 
 
eluting and paclitaxel-eluting stents. One hundred six patients were included who  
 
received either the sirolimus-eluting stents (n=54) or the paclitaxel-eluting stents (n=52)  
 
for the treatment of de novo lesions or in-stent restenosis (ISR).  
 
Primary endpoint was diameter stenosis (DS%) at follow-up. Angiographic secondary  
 
endpoints included late loss, rate of restenosis (defined as stenosis > 50% of luminal  
 
diameter), and the in-stent minimal luminal diameter (MLD) at follow-up. Clinical  
 
secondary endpoints were death rate, MI (Q-wave and non-Q wave, CABG, TLR, TVR  
 
and TVF at follow-up. 
 
Diameter stenosis (DS%) at follow-up was similar between the two groups (25.11± 
 
18.24% vs. 25.90 ± 21.23%;P=0.83, respectively). Minimal luminal diameter (MLD) at  
 
follow-up was also similar between the two groups (Cypher, 2.27 ± 0.62 mm vs.  
 
Paclitaxel, 2.34 ± 0.72 mm; P=0.57). Seven patients in the Cypher group and eight  
 
patients in the Paclitaxel group had binary restenosis (12.9% vs. 15.3%; P=0.65,  
 
respectively). Other angiographic parameters including late loss, acute gain, loss index,  
 
and net gain were similar between the two groups. Regarding clinical events, no one in  
 
either group suffered from MI or died or underwent bypass surgery. Also we did not find  
 
significant differences of TLR, TVR, and TVF between the two groups. 
In conclusion, Although some limitations apply, in particular the retrospective nature of  
our study and the small cohort size, our results suggest that  compared with the well  
established rapamycin-eluting stent, the paclitaxel-eluting stent without polymer-coating  
performs reasonably well. 
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7- Abbreviations: 
 
 
AHA:            American Heart Association. 
 
ACC:            American College of Cardiology. 
 
CABG:         Coronary Artery Bypass Graft. 
 
CAD:            Coronary Artery Disease. 
 
DCA:            Directional Coronary Atherectomy. 
 
DS:               Diameter Stenosis. 
 
EC:               Endothelial Cell. 
 
EEL:             External Elastic Laminea. 
 
I-B:               Inhibitory Protein-B 
 
ICAM-1:       Intercellular Adhesion Molecule-1. 
 
IEL:               Internal Elastic Laminea. 
 
IL:                 Interleukin. 
 
ISR:              In-Stent Restenosis. 
 
IVUS:           Intravascular Ultrasound. 
 
MACE:         Major Adverse Cardiac Events. 
 
MCP-1:         Monocyte Chemoattractant Protein-1. 
 
MI:                Myocardial Infarction. 
 
MLD:            Minimal Luminal Diameter. 
 
NF-B:            Nuclear Factor-B. 
 
PCI:               Percutenous Coronary Intervention. 
 
PTCA:           Percutaneous Transluminal Coronary Angioplasty. 
 
QCA:             Quantitative Coronary Angiography. 
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ROS:              Reactive Oxygen Spices. 
 
SVG:              Saphaneous Vein Graft. 
 
TLR:               Target Lesion Revascularization. 
 
TNF:               Tumor Necrosis Factor. 
 
TVF:               Target Vessel Failure. 
 
TVR:              Target Vessel Revasularization.            
 
VCAM-1:        Vascular Cell Adhesion Molecule-1. 
 
VSMC:           Vascular Smooth Muscle Cell. 
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